Fine interaction profiling of VemP and mechanisms responsible for its translocation-coupled arrest-cancelation
Abstract
Bacterial cells utilize monitoring substrates, which undergo force-sensitive translation elongation arrest, to feedback-regulate a Sec-related gene. Vibrio alginolyticus VemP controls the expression of SecD/F that stimulates a late step of translocation by undergoing export-regulated elongation arrest. Here, we attempted at delineating the pathway of the VemP nascent-chain interaction with Sec-related factors, and identified the signal recognition particle (SRP) and PpiD (a membrane-anchored periplasmic chaperone) in addition to other translocon components and a ribosomal protein as interacting partners. Our results showed that SRP is required for the membrane-targeting of VemP, whereas PpiD acts cooperatively with SecD/F in the translocation and arrest-cancelation of VemP. We also identified the conserved Arg-85 residue of VemP as a crucial element that confers PpiD-dependence to VemP and plays an essential role in the regulated arrest-cancelation. We propose a scheme of the arrest-cancelation processes of VemP, which likely monitors late steps in the protein translocation pathway.
Introduction
In bacteria, the evolutionarily conserved Sec translocon and SecA play essential roles in protein translocation across and integration into the membrane (Rapoport et al., 2017). The translocon consists of three membrane-integrated proteins, SecY, SecE, and SecG (Mori and Ito, 2001). SecY forms a channel-like path for substrate secretory proteins (Van den Berg et al., 2004) and is stabilized by SecE (Taura et al., 1993). SecG peripherally binds to SecY (Tanaka et al., 2015) and stimulates the SecA-dependent protein translocation (Nishiyama et al., 1994). SecA, an essential ATPase (Lill et al., 1989), binds to cytoplasmic protrusions in SecY (Mori and Ito, 2006a; Zimmer et al., 2008) and pushes a polypeptide into the translocon (Economou and Wickner, 1994; Erlandson et al., 2008). Secretory proteins are generally synthesized as a precursor with an N-terminal signal sequence recognized by the translocation machinery, including the translocon and SecA, and is cleaved off during translocation. Although bacterial protein secretion to the periplasmic space is thought to occur post-translationally in many cases, some secretory proteins use the signal recognition particle (SRP) pathway, which targets the nascent precursor protein to the translocon (Huber et al., 2005; Shimohata et al., 2005). Notably, even in the latter cases, translocation requires the SecA motor function (Shimohata et al., 2005). The Sec translocon is also utilized for protein integration into the membrane. Membrane proteins typically have no cleavable signal sequence, but their transmembrane (TM) regions act as a signal for integration. SRP binds to the signal sequence equivalent (a TM segment) of a membrane protein and deliverers a ribosome-nascent protein complex (RNC) to the translocon (Steinberg et al., 2018). The RNC binds to the same SecY region as SecA (Frauenfeld et al., 2011; Kuhn et al., 2011). Bacteria also have the SecD/F complex that stimulates protein secretion in vivo (Pogliano and Beckwith, 1994) and facilitates the release of a polypeptide from the Sec translocon during a late step in translocation (Matsuyama et al., 1993). Structural and functional analyses have shown that SecD/F is a H+-driven motor, in which its periplasmic domain (P1 head) binds a translocon-engaged substrate (Furukawa et al., 2017) and undergoes a conformational change coupled with the H+ flow (Tsukazaki et al., 2011). The repetitive movements of the P1 head would allow a forward movement of a translocating chain until its release to the periplasm.
Protein translocation and membrane insertion are essential biological processes in all living organisms, and it is reasonable that factors required for the localization are tuned according to cellular demands. Bacteria have acquired unique regulatory mechanisms by which either the expression of one of duplicated translocation/integration factors is specifically induced (V.SecD2/F2 in Vibrio alginolyticus (Ishii et al., 2015) (see the next section) and YidC2 (a membrane chaperone) in Bacillus subtilis Rubio et al., 2005) or a unique factor is upregulated (SecA in Escherichia coli) (Oliver and Beckwith, 1982) in response to a decline in the relevant transport activity of the cell. To monitor the cellular protein translocation activities and regulate the expression of the relevant factors in real-time, these bacteria utilize a special class of nascent polypeptides, called monitoring substrates (Ito et al., 2018), a class of regulatory nascent polypeptide (Tenson and Ehrenberg, 2002), which undergoes translation elongation arrest. Currently, three proteins are known: V. alginolyticus VemP (Ishii et al., 2015), B. subtilis MifM (Chiba et al., 2009), and E. coli SecM (Nakatogawa and Ito, 2001). Translation of these proteins is arrested by the specific interaction of their intrinsic amino acid sequences, called arrest sequences or arrest motifs, with the components of the ribosome. Remarkably, the arrest motifs of different monitoring substrates are diverse, with no apparent sequence similarities.
A marine bacterium, V. alginolyticus, possesses two sets of the secD/F genes, designated V.secD1/F1 and V.secD2/F2, whose products utilize Na+- and presumably H+-motive forces, respectively. The bacterium adapts quickly to a salinity change by replacing these SecD/F paralogues (Ishii et al., 2015). Although V.secD1/F1 is expressed constitutively, the expression of V.secD2/F2 is tightly repressed under Na+-rich growth conditions, but induced under low Na+ growth conditions. The vemP gene located upstream of V.secD2/F2 on the same operon plays an essential role in the regulated expression of V.secD2/F2. VemP, a substrate of the Sec machinery, monitors the machinery's activity via its own translocation. It undergoes stable translation-arrest before the canonical termination step under a protein translocation-deficient condition. In this scenario, the stalled ribosome on a vemP-V.secD2/F2 mRNA destabilizes a stem-loop structure in the vemP-V.secD2 intergenic region, leading to the exposure of an otherwise masked ribosome-binding site for the V.secD2 gene. Thus, the elongation arrest allows entry of ribosomes to that site and consequent synthesis of V.SecD2/F2. Importantly, the VemP translation-arrest occurs even under a protein translocation competent condition, but it is rapidly canceled presumably by a translocation-coupled pulling force that drives translocation of VemP.
Our previous in vivo studies showed that the majority of VemP has its signal sequence processed even in the arrested state. This strongly suggests that the arrest-cancelation of VemP occurs after its translocation has proceeded beyond the signal sequence processing event on the Sec translocon (Mori et al., 2018). Although this feature of VemP seems suitable for monitoring the SecD/F function, molecular mechanisms of how this is accomplished remain to be elucidated. To understand the detailed mechanism of the VemP-arrest-mediated regulation of the V.secD2/F2 expression, it is crucial to know the dynamic interactions of VemP with other participating proteins during the arrest and its translocation-coupled cancelation processes.
Site-directed in vivo photo-crosslinking is a well-designed technique for analysis of inter- or intra-molecular interactions of proteins in living cells (Chin and Schultz, 2002), wherein a pair of a mutated tRNA and an engineered tyrosyl-tRNA synthetase allows for in vivo incorporation of a photo-reactive amino acid analog, p-benzoyl-L-phenylalanine (pBPA), into any selected positions of a target protein by amber suppression (Chin et al., 2002). Upon UV irradiation, pBPA in the target protein generates a covalent crosslinking with nearby molecules. Identification of crosslinked partners provides detailed information about interactions with them at an amino acid residue level resolution, proving useful for many studies (Miyazaki et al., 2020). To extend this technique to acquire temporal resolution, we recently developed the PiXie (pulse-chase and in vivo photo-crosslinking experiment) method. This new approach entails the use of an ultra-powerful UV irradiator that shortens the UV-irradiation time so that we can combine photo-crosslinking and pulse-chase approaches. It enables us to trace dynamic in vivo folding/assembly processes of newly synthesized proteins with high temporal (in the sub-minute order) and spatial (the amino acid residue level) resolutions (Miyazaki et al., 2018). Since a similar orthogonal tRNA/tRNA synthetase system for pBPA introduction is not available for V. alginolyticus, we cannot directly apply the PiXie method to the cognate bacterium to identify interactors of VemP. Vibrio species are closely related to enterobacteria including E. coli and possess a single copy of the secA, secY, secE, secG, and ffh (encoding the protein component of SRP) genes. Because each of the SecA (Kunioka et al., 1998), SecY (Bhattacharyya and Das, 1997), SecE (Nishiyama et al., 1998) and the two SecD/F (Ishii et al., 2015) homologs of Vibrio can function in E. coli cells, the basic structure and function of the Sec machinery and the interaction modes among these factors should be well conserved between these species. Therefore, photo-crosslinking analysis in E. coli would allow us to identify candidate proteins interacting with a VemP-nascent polypeptide in living cells.
In this study, we performed a non-biased, systematic PiXie analysis of VemP and investigated the factors that interact with a VemP-nascent polypeptide during its biosynthesis in E. coli. The physiological significance of the interactions observed in E. coli was evaluated by genetic and biochemical analysis in Vibrio cells. In addition, we identified an amino acid residue of VemP that imposes PpiD-dependence and thereby participates in the force-sensing regulation. Based on these analyses, we discuss how VemP integrates its translocation and arrest regulation for the real-time feedback regulation of the late step motor protein, SecD/F.
Results
In vivo crosslinking reveals interaction of a VemP nascent polypeptide with Ffh and PpiD as well as uL22 and translocon
VemP is a Sec-monitoring substrate in V. alginolyticus that monitors cellular protein secretion activity via its own translation arrest (Ishii et al., 2015). To identify proteins interacting with a VemP nascent polypeptide, we conducted a systematic PiXie analysis by expressing in E. coli a series of VemP-3xFLAG-Myc (VemP-F3M) derivative having pBPA at various positions. We distinguished three VemP species, arrested polypeptide having unprocessed signal sequence (AP-un), arrested polypeptide whose signal sequence has been proteolytically processed (AP-pro), and the full-length mature protein (FL-m) (Mori et al., 2018) based on their mobilities on SDS-PAGE (Figure 1). The site of the pBPA-introduction varied from the position for the Leu-9 to the one for Phe-131. In growing cells, VemP was initially produced as the arrested forms, which were converted to FL-m with a half-life of ~0.5 min (Mori et al., 2018). To follow the interaction profiles in this rapid process, we used the PiXie method (Miyazaki et al., 2018) (See Materials and methods), which indeed revealed the pBPA-dependent generation of higher molecular mass bands (indicated by colored arrow-heads) indicative of the formation of crosslinked products (XLs) (Figure 1—figure supplement 1A,B). To identify factors physiologically interacting with VemP during its biogenesis process, we focused on XLs that gradually decreased during the chase periods (see the next section). For instance, we eliminated an XL of ~150 kDa, observed for the VemP(L40pBPA) variant, for the further analysis, because, while immunoprecipitatable with an anti-SecA antibody (Figure 1—figure supplement 2A), it remained stable during the chase periods, in sharp contrast to other XLs observed for VemP derivatives having a pBPA at position either 56 or 124 (Figure 1—figure supplement 2B and see the next section). The XL of ~150 kDa would represent the adduct between SecA and VemP, but not reflect physiological interactions that occur during translocation of VemP.

In vivo crosslinking reveals interaction of a VemP nascent polypeptide with Ffh and PpiD as well as uL22 and translocon.
(A) Summary of proteins crosslinked with VemP in the arrested state. Colored circles represent the positions at which crosslinking with the indicated proteins was observed in B–F. Dashed red line shows the positions at which cross-linking with PpiD was detected in Figure 1—figure supplement 1. (B–F) PiXie analysis of VemP. Wild type E. coli cells were used in B and C. E. coli cells expressing SecY-His10, Ffh-His10, or PpiD-His10 from the chromosome were used in D, E and F, respectively. Wild type cells were used as negative controls in D, E and F. Cells were grown, induced to express a VemP-F3M derivative and pulse-labeled with [35S]Met for 30 s, followed by 30 s-chase as described in Materials and methods. Cells were UV-irradiated for 1 s and immediately acid-treated. Labeled proteins were subjected to immunoprecipitation (IP) or pull-down (PD) with Ni-NTA agarose, separated by SDS-PAGE and analyzed by phosphorimaging. The result shown is a representative of two independent experiments that were conducted using the same transformants (i.e. two technical replicates). Asterisks represent crosslinked dimers of VemP-F3M. An enlarged view around Trp-124 of VemP in a VemP-stalled ribosome complex (PDB:5nwy; Su et al., 2017) is shown in B, left.
An XL of ~30 kDa, observed for the VemP(W124pBPA) variant, was immunoprecipitatable with an anti-uL22 antibody (Figure 1B, right). The proximity of Trp-124 to uL22 in vivo is consistent with a recent cryo-EM study showing that Trp-124 of arrested VemP is positioned close to the ribosomal protein uL22 (Figure 1B, left) (Su et al., 2017). VemP(F81pBPA) and VemP(T83pBPA) generated XLs of ~25 kDa. We envisioned that the crosslinked partner could either be SecE (~14 kDa) or SecG (~12 kDa), small components of the translocon, because VemP engages in the Sec-dependent translocation (Mori et al., 2018). We reasoned that these XLs contained SecG because they reacted with an anti-SecG antibody (Figure 1C and Figure 1—figure supplement 3A) and disappeared in the ΔsecG strain (VemP(F81pBPA); Figure 1—figure supplement 3A). To investigate possible crosslinking with SecY, the main component of the translocon, we used a host strain having a chromosomal secY-his10 gene. We detected the SecYxVemP XLs for the VemP derivatives having pBPA in a middle region (Arg-74, Asp-76, Leu-78, Asn-82, and Trp-86) of VemP among materials pulled-down by polyhistidine affinity isolation (Figure 1D and Figure 1—figure supplement 4A). Thus, the middle region of the newly synthesized VemP chain contacts the translocon.
For this interaction to occur, VemP might use some targeting mechanism that delivers it to the translocon. SecM, the Sec-monitoring substrate in E. coli was suggested to depend on the SRP pathway (Nakatogawa and Ito, 2001), which consists of the 4.5S RNA and the signal sequence-recognition subunit, Ffh. We found that VemP also interacts with SRP through the PiXie analysis using a strain carrying chromosomal ffh-his10. Placement of pBPA within the signal sequence (Ala-15 position) allowed for the generation of a VemPxFfh XL that was His-tag affinity isolated (Figure 1E and Figure 1—figure supplement 4B). We suggest that SRP recognizes the signal sequence of VemP.
Placement of pBPA at the C-terminal vicinity of the signal sequence (residue 30 to 60) led to the generation of XLs with apparent molecular sizes of ~75–100 kDa (Figure 1—figure supplement 1A,B). As partner candidates, we highlighted YidC (~60 kDa) (Kuhn et al., 2017), SecD (~68 kDa) (Tsukazaki, 2018), and PpiD (~69 kDa) (an inner membrane-anchored periplasmic chaperone) (Antonoaea et al., 2008) based on their sizes and their involvement in protein translocation. We addressed the possibility of their involvement using their His-tagged derivatives and found that a XL was His-tag affinity-isolated when a cell with chromosomal ppiD-his10 was used (Figure 1F), but not with the other his10 constructs (Figure 1—figure supplement 4C,D). Furthermore, the XL was immunoprecipitated with an anti-PpiD antibody and were not generated in a ΔppiD cell (Figure 1—figure supplement 3B). These results indicate that PpiD interacts with the VemP region (Tyr-36 to Ser-60) that follows the periplasmic end of the signal sequence.
None of the VemP XLs with uL22, Ffh, SecG, SecY, and PpiD described above were immunoprecipitated with the anti-FLAG antibody (Figure 1—figure supplement 5), indicating that the VemP component in these XLs lacks the C-terminal tag and, therefore, are in the elongation-arrested state. It follows then that each of the partner proteins binds to the nascent VemP'-tRNA tethered to the ribosome. In addition to the above XLs, we observed ~37 kDa XLs with a number of VemPpBPA derivatives (Figure 1—figure supplement 1), some of which proved to be immunoprecipitable with the anti-FLAG antibody (Figure 1—figure supplement 5). We interpret that these ~37 kDa XLs represent dimer forms of FL-m generated in the periplasm. Thus, we did not analyze these XLs any further. Although some of other XLs shown in Figure 1—figure supplement 1 could represent VemP-crosslinking with still un-identified cellular factors involved in the arrest/cancelation process of VemP, we did not conduct further analysis in this study. Figure 1A summarizes the crosslinking features of nascent VemP polypeptide.
The VemP nascent polypeptide interacts sequentially with uL22/Ffh, the translocon, and PpiD
To gain insight into the timing and order of the molecular interactions involving VemP, we next examined in vivo stability of the XLs during the chase period using appropriate pBPA variants. The intensities of the radioactivities associated with the arrested and non-crosslinked VemP decreased during the chase period due to the secretion-coupled arrest cancelation. While XLs intensities also declined during the chase (Figure 2A,B and Figure 2—figure supplement 1), a careful comparison of the decrease rates showed that the kinetics of the XLs decrease did not always coincide exactly with that of the arrested-VemP. While the decrease rates of the SecG-XLs and the arrested VemP were almost the same, the uL22- and Ffh-XLs decreased slightly faster than the arrested VemP (Figure 2B,C and Figure 2—figure supplement 2). These results suggest that Ffh (SRP) and uL22 interact with the arrested VemP polypeptide before targeting to the translocon, in agreement with their cellular functions and localization. This was verified by examining the effect of NaN3, a SecA inhibitor, on the VemP-crosslinkings. NaN3 treatment of cells causes the stabilization of the AP-un form of VemP in living cells (Mori et al., 2018), suggesting that inhibition of SecA prevents VemP from initiating its translocation into the translocon. We confirmed it by pulse-chase experiments using a secA51 (Ts) mutant cells (Figure 2—figure supplement 3). As expected, the arrest cancelation of VemP was severely and specifically retarded at high temperature in the secA51(Ts) mutant cells, but not in its isogenic wild type cells. We found that the NaN3 treatment increased the VemP crosslinking with uL22 and Ffh, but decreased its crosslinking with SecY, SecG, and PpiD (Figure 2—figure supplement 4A,B). These results suggest that the arrested VemP interacts with SRP and uL22 before the interactions with the translocon and PpiD on the membrane. In contrast to the uL22- and Ffh-XLs, the PpiD-XLs tended to decrease more slowly than SecG-XLs or the arrested VemP (Figure 2B,C). This suggests that VemP is recognized by PpiD after it engages with the translocon, being consistent with the topology of PpiD that has a functional domain in the periplasm.

The VemP nascent polypeptide interacts sequentially with uL22/Ffh, the translocon, and PpiD.
(A) PiXie analysis of VemP. Cells were grown, induced to express a VemP derivative with pBPA, pulse-labeled and chased as in Figure 1. At the indicated time points in the chase period, cells were UV-irradiated for 1 s and then acid-treated. Labeled proteins were subjected to IP with an anti-VemP antibody or pull-down with Ni-NTA agarose. The same strains were parallelly pulse-labeled, chased, and subjected to IP with the anti-VemP antibody without the UV irradiation. Isolated proteins were analyzed as in Figure 1. Portions of the gel images showing the XLs (upper gels) or showing the VemP-derived bands of the UV-unirradiated samples (lower gels) are presented. Full images of the gels for all the results are presented in Figure 2—figure supplement 1B. The result shown is a representative of three biological replicates. (B) Relative amounts of the VemP arrested forms and the VemP-XLs. The band intensity of VemP-FL (open diamonds), VemP-APs (AP-un + AP-pro) (closed diamonds), and XLs (colored symbols) in A was quantitated and the mean values of the relative values (the value at the 0.5 min was set to 1) were plotted (error bars are S.D.; (n = 3)). The detail procedure for quantification of immunoprecipitated bands in a representative result is presented in Figure 2—figure supplement 2. (C) Relative crosslinking efficiency of the arrested VemP. The values for the relative intensities of XLs at 1 min to the corresponding average intensities of VemP-APs were calculated from the results in B. The mean values are shown with S.D. (n = 3 biological replicates). See Figure 2—source data 1 for gel images and quantitated band intensities data for A–C.
-
Figure 2—source data 1
Zip file containing gel images and quantified band intensity data for the PiXie experiments.
- https://cdn.elifesciences.org/articles/62623/elife-62623-fig2-data1-v2.zip
Ffh (SRP) functions in the targeting of VemP
We examined the role of Ffh (SRP) in the membrane translocation and arrest-cancelation of VemP by pulse-chase experiments using an E. coli strain, WAM121, in which ffh is transcribed from the arabinose promoter (de Gier et al., 1996). The Ffh-depletion upon removal of arabinose from the medium stabilized the AP-un form of VemP (Figure 3A), indicating an impairment of the targeting of the VemP-ribosome complex to the translocon. Consistent with the observation, deletion of the secB gene that encodes a secretion-specific chaperone severely compromised export of MBP, a SecB-dependent substrate, but exhibited the normal arrest cancelation of VemP (Figure 3—figure supplement 1), supporting the co-translational targeting of a VemP-ribosome complex. The prolonged translation-arrest of VemP is expected to induce the expression of the downstream V.secD2/F2 genes (Ishii et al., 2015). To verify this point, we examined the V.SecD2 expression in WAM121 cells carrying a vemP-V.secD2/F2 plasmid, and found that the synthesis of V.SecD2 was indeed elevated under the Ffh-depleted conditions (Figure 3B). We also examined the effect of an Ffh-depletion on the V.SecD2 expression in the cognate organism, V. alginolyticus (Figure 3C). Under a Na+-rich growth condition, the Na+-driven V.SecD1/F1 in this organism was fully functional, leading to the efficient arrest cancelation of VemP and consequent tight repression of V.SecD2 (Ishii et al., 2015). In the Ffh-depletable strain of V. alginolyticus with the arabinose promoter-controlled ffh, the V.SecD2 expression was induced in the arabinose-free medium even in the presence of a sufficient level of Na+, consistent with the notion that the Ffh-depletion compromises the targeting of VemP and stabilizes its translation arrest. These results suggest that SRP is crucial for the translocon targeting of VemP, which is a prerequisite for the proper regulation of the V.SecD2/F2 expression in Vibrio.

Ffh (SRP) functions in the targeting of VemP.
(A) Effects of Ffh-depletion on stability of the arrested-VemP. (left) Ffh-depletable cells carrying a vemP-f3m plasmid were grown in the M9 medium with (+) or without (–) 0.05% arabinose, induced, pulse-labeled and chased as in Figure 1. At the indicated chase time points, total cellular proteins were acid-precipitated, subjected to IP and analyzed as in Figure 1. (middle) In parallel, a portion of the cultures just before pulse-labeling was subjected to immunoblotting (IB) analysis with an anti-Ffh antibody. (right) Percentages of the arrested VemP in left were calculated by the equation described in Materials and methods. Values are means ± S.D. (n = 3 technical replicates). (B) Effects of Ffh-depletion on the expression of V.secD2. (left) The Ffh-depletable cells carrying an empty vector or a vemP-V.secD2/F2 plasmid (WT) were grown, induced, and pulse-labeled for 1 min. Total cellular proteins were acid-precipitated. For the WTNaN3 samples, the cells carrying the vemP-V.secD2/F2 plasmid were pretreated with 0.02% NaN3 for 5 min before pulse-labeling. Labeled proteins were subjected to IP, and analyzed as in Figure 1. (middle) In parallel, a portion of the cultures just before the pulse-labeling was subjected to IB with the anti-Ffh antibody. The intensity of the V.SecD2 band from each lane was quantitated. Values are means ± S.D. (n = 3 technical replicates) (the value for WT in the presence of arabinose was set to 1). (C) Effects of Ffh-depletion on the expression of V.secD2 in a Vibrio cell. (left) The Vibrio cells indicated were grown at 30°C in VC-medium with (+) or without (–) 0.2% arabinose for 3 hr. Total cellular proteins were acid-precipitated, and analyzed by IB. (right) The intensity of the V.SecD2 band from each lane was quantitated. Values are means ± S.D. (n = 3 technical replicates) (the value for the ΔV.secD1/F1 cells in the presence of arabinose was set to 1). The asterisks (*, **, ***) in B and, C represent un-related proteins recognized by the indicated antibodies. See Figure 3—source data 1 for gel images and quantitated band intensities data for A–C.
-
Figure 3—source data 1
Zip file containing gel images.
(A–C) and quantified band intensity data for the pulse-chase experiments using the anti-VemP antibody (A), pulse-labeling experiments using the anti-SecD2 antibody (B) and immunoblotting with the anti-SecD2 antibody (C).
- https://cdn.elifesciences.org/articles/62623/elife-62623-fig3-data1-v2.zip
PpiD and SecD/F cooperate to facilitate the translocation and the arrest cancelation of VemP
We then carried out functional studies of PpiD, identified in this study as a crosslinking partner of VemP. Pulse-chase analysis showed that VemP was kept in the arrested state much more stably in the ΔppiD cells than in the ppiD+ E. coli cells (Figure 4A). We note that translocation of a secretory protein MBP (maltose-binding protein) was also retarded by the ppiD disruption, albeit less pronouncedly (Figure 4A). The loss of ppiD increased the V.SecD2 expression in E. coli (Figure 4B) and in Vibrio (Figure 4C). These results show that PpiD plays a crucial role in the arrest-cancelation of VemP. The PpiD disruption caused an accumulation of the AP-pro form of VemP in contrast to the Ffh depletion that led to the AP-un accumulation (compare Figures 3A and 4A). These results support the notion that PpiD acts on the periplasmic side after the signal sequence cleavage of the arrested VemP, whereas Ffh acts earlier on the cytosolic side. Our kinetic analysis already showed that PpiD is crosslinked to VemP at a late step of its translocation processes (Figure 2).

PpiD and SecD/F cooperate to facilitate the translocation and the arrest cancelation of VemP.
(A) Effects of the ppiD disruption on the stability of the arrested-VemP. (left) WT cells or ΔppiD cells carrying the vemP-f3m plasmid were grown, induced, pulse-labeled, and chased as in Figure 1. At the indicated chase time points, total cellular proteins were acid-precipitated and subjected to IP and analyzed as in Figure 1. (right) The mean values of arrested VemP (%) are plotted with S.D. (n = 3 technical replicates). (B) Effects of the ppiD disruption on the expression of V.secD2. (left) WT cells or ΔppiD cells carrying either an empty vector or a vemP-V.secD2/F2 plasmid (WT) were grown, induced as in A and pulse-labeled for 1 min. For the WTNaN3 samples, the cells carrying the vemP-V.secD2/F2 plasmid were pretreated with 0.02% NaN3 for 5 min before pulse-labeling. Labeled proteins were subjected to IP and analyzed as in Figure 1. The intensities of the V.SecD2 bands were quantitated. Values are means ± S.D. (n = 3 technical replicates) (the value for the WT cells was set to 1). (C) Effects of the ppiD disruption on the expression of V.secD2 in Vibrio cells. (left) The indicated Vibrio cells were grown at 30°C in the VC-medium for 2 hr. Total cellular proteins were acid-precipitated and subjected to IB. (right) The intensities of the V.SecD2 bands were quantitated. Values are means ± S.D. (n = 3 technical replicates) (the value for the ΔV.secD1/F1 cells was set to 1). The asterisks (*, **, ***) in B and C represent un-related proteins recognized by the indicated antibodies. (D) Roles of SecD/F and PpiD in the arrest-release of VemP. A pRM83c-based plasmid carrying either his10-secD/F or ppiD, or the empty vector was introduced, in addition to pHM1021-vemP-f3m, into wild type cells and cells having either the secD1 or the ΔppiD mutation. These cells were grown at 37°C for 2.5 hr as in Figure 1. A half of the cell cultures were removed and acid-treated. Precipitated proteins were subjected to IB (lower two panels). The remaining cells were induced with 1 mM IPTG for 15 min, pulse-labeled for 30 s and chased for 30 s. Acid-precipitated proteins were subjected to IP and analyzed as in Figure 1 (upper two panels). The result shown is a representative of two technical replicates. The asterisk in the lowest gel represents a degradation product of PpiD. (E) In vivo photo-crosslinking of SecD with PpiD. Cells were grown in L medium containing 0.5 mM pBPA until early log phase at 37°C and induced with 0.02% arabinose for 1 hr to express the indicated SecD/F variants. The cultures were divided into two portions, each of which was treated with or without UV-irradiation for 10 min at 4°C. Total cellular proteins were acid-precipitated and subjected to IB. The result shown is a representative of two technical replicates. A crystal structure of SecD/F (PDB:3aqp; Tsukazaki et al., 2011) is shown in the left. See Figure 4—source data 1 for gel images and quantitated band intensities data for A–C.
-
Figure 4—source data 1
Zip file containing gel images.
(A–C) and quantified band intensity data for the pulse-chase experiments using the anti-VemP antibody (A), pulse-labeling experiments using the anti-SecD2 antibody (B) and immunoblotting with the anti-SecD2 antibody (C).
- https://cdn.elifesciences.org/articles/62623/elife-62623-fig4-data1-v2.zip
Next, we addressed how PpiD participates in the arrest cancelation of VemP, whose role is to regulate the expression of SecD/F that facilitates a late step of translocation (Mori et al., 2018). The role of SecD/F itself in the VemP arrest cancelation can be seen from the prolonged VemP arrest in the secD1 (a mutation causing SecD/F depletion) E. coli cells (Figure 4D, vector lanes) and the enhanced arrest cancelation by overproduction of SecD/F (Figure 4D, left, vector vs. secD/F). As both SecD/F and PpiD are involved in later steps of VemP translocation, they might cooperate in canceling the elongation arrest. Alternatively, they might have redundant functions. The arrested state of VemP was stabilized in the ΔppiD cells (Figure 4D, vector lanes), showing that its function is required for the active translocation and the arrest cancelation of VemP. Whereas the overproduction of PpiD facilitated the arrest cancelation, as expected, SecD/F's overproduction was ineffective in relieving the arrested state due to the ppiD defect. Conversely, PpiD overproduction was ineffective in relieving the arrested state due to the secD1 mutation (Figure 4D). These results rule out the possibility that the roles of SecD/F and PpiD in arrest cancelation are redundant. Instead, both of them are specifically required for the cancelation of VemP arrest, raising the possibility that they interact with each other. We then studied this point by in vivo photo-crosslinking. When pBPA was incorporated into the position of Asp-359 in the P1 head of SecD, its XLs with PpiD were detected (Figure 4E). Thus, PpiD resides in close proximity to the mobile P1 head of SecD of the VemP-translocating translocon. Generation of the two XLs could represent crosslinking of pBPA at position 359 in SecD to two different positions in PpiD.
Conserved Arg-85 has a role in the regulation of secretion-coupling of the VemP arrest cancelation
Our systematic pBPA scanning incidentally revealed that incorporation of this amino acid analog to some VemP residues compromised the translation arrest of VemP (Figure 1—figure supplement 1A and Figure 5—figure supplement 1A). We selected several residues among them (shown in Figure 5—figure supplement 1B), and replaced them individually with Trp (having a bulky, hydrophobic side chain like pBPA). The Trp substitutions destabilized the translation arrest in similar ways to the corresponding pBPA substitutions. Among them, the R85W mutation had the strongest effect; it decreased the ratio of arrested forms to total VemP to the level comparable with that observed with a previously identified arrest motif mutation, W143A (Mori et al., 2018). Several other replacements of Arg-85 by residues of different properties also impaired apparently the translation arrest of VemP (Figure 5A). The R85W mutation abrogated the arrest-mediated up-regulation of V.secD2 (Figure 5—figure supplement 1C). These results showed that Arg-85 is crucial for the stable translation arrest of VemP in vivo.

Conserved Arg-85 has a role in the regulation of secretion-coupling of the VemP arrest cancelation.
(A) Effects of Arg-85 mutations on the stability of the arrested VemP in vivo. Cells were grown, induced to express the indicated VemP-F3M derivatives, and used for the pulse-chase experiments as in Figure 4A. Labeled proteins were subjected to IP with an anti-VemP antibody and analyzed as in Figure 1. The result shown is a representative of three technical replicates. (B) Behavior of the VemP(R85W) mutant under Sec-deficient conditions. Cells defective in protein translocation (secY24/pSTV28-syd) expressing the indicated VemP-F3M derivatives were examined by the pulse-chase experiment as described in Figure 4A except that the export of MBP was also examined by IP with an anti-MBP antibody. The result shown is a representative of two technical replicates. (C) Effects of the R85W mutation on translocation of the VemP(F.S.) derivative that undergoes no translation arrest. WT cells or ΔppiD cells were grown, induced to express the indicated VemP(F.S.)-F3M derivatives, and used for the pulse-chase experiments as in Figure 4A. Labeled proteins were subjected to IP with an anti-VemP antibody and analyzed as in Figure 1. The result shown is a representative of three biological replicates.
We conceived two possibilities that account for the observed phenotypes of the Arg-85 mutations. First, this residue belongs to the arrest sequence, although it presumably resides outside of the ribosome in the arrested translation complex. In this case, the Arg-85 mutations simply lead to a loss of arrest proficiency. Secondly, Arg-85 regulates the arrest proficiency by partially antagonizing the secretion-coupled arrest cancelation. In this scenario, the Arg-85 mutation may sensitize the VemP nascent chain to the secretion-generated pulling force and consequently lead to the apparent arrest-defective phenotype in vivo. To distinguish these possibilities, we examined the VemP(R85W) mutant protein behaviors under secretion-defective conditions. In the Sec-deficient cells (see Materials and methods), the arrested form of WT VemP was stabilized (Mori et al., 2018), while that of VemP(W143A) was rapidly converted to the full-length form (Figure 5B). In contrast, the R85W mutant did not exert a negative effect on the arrest in the secretion-impaired cell (Figure 5B). As another means to render VemP indifferent to secretion, we deleted its signal sequence. The R85 mutation did not affect the elongation arrest in the absence of the signal sequence. By sharp contrast, the W143A mutation abolished the arrest even in the absence of the signal sequence (Figure 5—figure supplement 1D). Thus, the mode of involvement of Arg-85 in the elongation arrest is fundamentally different from that of Trp-143.
These data revealed that Arg-85 acts after targeting of the VemP-ribosome complex to the translocon, probably during its translocation. To examine the role of Arg-85 in the SecD/PpiD-dependent translocation of VemP, we examined the effects of the R85W and W143A mutation of VemP, individually or in combination on translocation of VemP in wild type and ΔppiD strains (Figure 5—figure supplement 2). In the ΔppiD strain, while a significant fraction of the VemP(W143A) was retained in the arrested forms, the VemP(R85W/W143A) double mutant was almost completely translocated to generate the mature (processed) FL form. The results suggest that the R85W mutation allows the efficient translocation of VemP even in the absence of PpiD, indicating that the mutation at Arg-85 reduces PpiD-dependency of the VemP translocation. To evaluate the role of Arg-85 in the VemP translocation without the elongation arrest, we used the VemP(F.S.) mutant, in which the arrest motif sequence had been replaced with a completely different amino acid sequence by a frame shift (F.S.) mutation (Mori et al., 2018), and assayed the VemP translocation in the wild type and the ΔppiD strains by pulse-labeling (Figure 5C). As expected, the VemP(F.S.) derivative no longer underwent the elongation arrest even in the ΔppiD strain. We observed a small but significant amount of the full-length precursor form of VemP(F.S.) in the ΔppiD strain, suggesting the translocation of VemP(F.S.) depends on PpiD. Interestingly, the additional introduction of the R85W mutation into VemP(F.S.) greatly reduced the amount of the precursor. These results indicate that while the Arg-85 residue somehow retards the translocation of VemP independently of its translation arrest, it is released by the function of PpiD; in other words, Arg-85 imposes PpiD-dependency on the translocation of VemP. The function of Arg-85 could repress the arrest cancelation of VemP until translocation of VemP proceeds to an appropriate stage, at which PpiD and SecD/F come in to enhance the late stage of translocation.
Discussion
VemP in Vibrio controls the SecD/F expression through its force-sensitive translation arrest. Although we previously suggested that the arrest cancelation of VemP is coupled to a late step of translocation (Mori et al., 2018), the details of the responsible force and how this regulatory process occurs remain largely unknown. To understand the molecular mechanisms that lead to the elongation arrest and its cancelation, we performed a systematic PiXie analysis of VemP, which allowed us to identify cellular factors that sequentially interact with the newly synthesized VemP polypeptide chain. We previously used the PiXie method, which allows precisely time-controlled and residue-specific crosslinking, to analyze the post-translational maturation processes of protein complexes with different cellular localizations in bacteria (Miyazaki et al., 2018). This method should also be useful for studying co-translational events (Kramer et al., 2019; Pechmann et al., 2013) that a nascent polypeptide experiences during translation. In particular, a class of polypeptides that undergoes translation arrest would be suitable targets of the PiXie analysis. The molecular interaction behaviors of such arrest peptides, including bacterial VemP, SecM, MifM, and mammalian XBP1u (Chiba et al., 2009; Ishii et al., 2015; Nakatogawa and Ito, 2002; Yanagitani et al., 2011), would be highly relevant for our understanding of these nascent polypeptides in the cell. Thus, in this work, we applied the PiXie method to VemP, which we have identified and characterized previously (Ishii et al., 2015).
We identified Ffh and PpiD as factors directly interacting with the arrested VemP in addition to the ribosomal protein uL22 and the translocon components (Figure 1). The kinetic analyses suggest their sequential interactions with VemP (Figure 2); VemP initially interacts with uL22 and the cytosolic Ffh, then with the membrane-embedded translocon, and lastly with PpiD, a periplasmically exposed chaperone. The crosslinking of VemP with Ffh and PpiD should have functional significance rather than representing a result of a non-specific collision of VemP with these proteins, as suggested by our genetic analyses using the Ffh-depletable and the ppiD deletion strains. The observation that the distinct regions in VemP interact with uL22, Ffh, the translocon, and PpiD (Figures 1 and 6A, left) is consistent with pre-targeting interactions of the arrested VemP with uL22 and Ffh and a post-targeting interaction with PpiD (Figure 6A, right) (see Appendix1: Interactions of a VemP nascent chain with Sec translocon and the related components). A cryo-EM study showed that a VemP nascent polypeptide in the ribosomal exit tunnel forms a compacted secondary structure (Su et al., 2017). In this structure, Trp-124 of VemP contacts to the uL22 protein. The observed crosslinking of pBPA at Trp-124 with uL22 is consistent with the reported structure. Interestingly, we found that the crosslinking representing the VemP-uL22 interaction was enhanced markedly when cells were treated with NaN3 that should have compromised an early step of the VemP translocation by inhibiting SecA. Thus, the VemP's interaction with uL22 occurs before its initial insertion into the translocon (Figure 2—figure supplement 4).

A model of the arrest-cancelation of a VemP nascent polypeptide.
(A) Schematic interaction maps of VemP during its translocation processes. The positions of the crosslinking with other factors and Arg-85 are mapped on the schematic picture of the arrested VemP-ribosome complex (left). Hypothetical models of the nascent VemP-ribosome complex on the Sec machinery (right). See the text for details. (B) An overview of the translocation processes of the arrested VemP including the arrest-cancelation steps. See the text for details.
We suggest that VemP in the ribosomal tunnel changes its conformation from the compacted state to some other state, perhaps a more extended one, as the translocation process proceeds, because the structural determination had used a nascent chain-ribosome complex without any translocation factors (Su et al., 2017; Figure 6A, right). It is conceivable that a pulling force generated by translocation acts to disrupt the VemP secondary structure and, consequently, the molecular interactions required for the elongation arrest.
We propose the following scheme for the targeting and translocation processes of VemP accompanied by the translation-arrest and its cancelation (Figure 6B). (i) In the cytosol, SRP recognizes and binds to the signal sequence of VemP and targets the nascent chain to the translocon. During this co-translational targeting step, the ongoing translation of VemP is subject to elongation arrest. The use of the SRP pathway, in conjunction with the amino acid sequence features of its signal sequence (Yap and Bernstein, 2011) and the early mature part (see below), might ensure the timely release of the translation complex from the translation-arrested state. (ii) The signal sequence is then inserted into the lateral gate region while the mature region of VemP is going to span the translocon's polypeptide-conducting channel. This early step of translocation is facilitated by the SecA ATPase (Figure 2—figure supplement 3) and accompanied by the signal sequence cleavage. Therefore, the inhibition of SecA with NaN3 causes accumulation of the AP-un form of VemP. (iii) SecD/F and PpiD then interact with VemP and cooperate in canceling the translation arrest of VemP while aiding its further translocation. (iv) Finally, the full-length, mature VemP polypeptide is exported to the periplasm.
In the arrest cancelation event, PpiD and SecD/F seem to cooperate either sequentially or in concert, and our crosslinking results revealed that they physically interact with each other (Figure 4E). PpiD was a member of the periplasmic chaperone network (Dartigalongue and Raina, 1998; Matern et al., 2010), which directly interacts with both SecY/E/G and ribosome-tethered polypeptides (Antonoaea et al., 2008; Sachelaru et al., 2014). Although an in vitro study revealed that PpiD stimulates translocation of substrate proteins (Fürst et al., 2018), the deletion of the ppiD gene caused no detectable defect of outer membrane protein biogenesis (Justice et al., 2005). We found that the translocation of MBP was compromised weakly in the ΔppiD strain (Figure 4A). At any rate, the exact role of PpiD in protein export remains obscure. We showed here that PpiD physically contacts SecD as well as the AP-pro form of VemP in vivo. Furthermore, our genetic and biochemical analyses indicated that PpiD has a role in the cancelation of the VemP translation arrest (Figure 4). Although our experiments failed to detect a VemP-SecD crosslinking, due possibly to the transient/unstable nature of their interaction, SecD/F also functions in the arrest cancelation of VemP (Figure 4D). We propose that PpiD and SecD/F cooperate to facilitate translocation and arrest-cancelation of VemP.
SecD/F works as a monovalent cation-driven motor that pulls up a translocating polypeptide by undergoing a conformational change of the P1 head (Tsukazaki et al., 2011). Such an action could generate a pulling force that cancels the VemP elongation arrest. By contrast, PpiD itself would not generate a pulling force against the nascent chain because it is an ATP-independent chaperone (Matern et al., 2010). It is conceivable that PpiD captures a VemP polypeptide emerging from the translocon and then hand it over to the P1 head domain, which is known as the substrate-binding site of SecD (Furukawa et al., 2017). Possibly, the direct contact between PpiD and SecD facilitates the substrate transfer from PpiD to SecD. It is also possible that the binding of VemP by PpiD helps to prevent the reverse movement of VemP. Since both SecD/F and PpiD are well conserved in enterobacteria including E. coli that possess no VemP protein, the co-operative function of these proteins could be utilized to stimulate late step translocation of some un-identified secretory proteins in these organisms. Although further studies including identification of contact sites of PpiD with the P1 head of SecD and the detailed in vitro study of the late step translocation of VemP and other substrates are needed, it is noteworthy that bacterial species appear to be equipped with a dedicated pulling system acting from the extra cytosolic location for protein secretion and translational control.
We identified Arg-85 as a cis-element important for the in vivo stability of the translation-arrest of VemP, through its role in the regulation of the translocation coupling of the arrest-cancelation. Arg-85 is highly conserved among the VemP orthologues (Figure 5—figure supplement 3), pointing to its importance in the VemP function. This residue does not contribute to the establishment, per se, of the translation-arrested state of VemP, when its secretion is blocked (Figure 5B). However, under the export-proficient conditions, Arg-85 somehow acts to retard the translocation of VemP independently of the translocation arrest of VemP, and consequently increase the PpiD-dependency of the VemP translocation (Figure 5C). Our crosslinking results show that a region encompassing the Arg-74 to Trp-86 interval interacts with the translocon's components in the arrested state of VemP (Figure 6A), indicating that Arg-85 resides in the SecY/E/G-contacting region of the VemP nascent chain (Figure 6A). This spatial arrangement leads us to assume that Arg-85 interacts with the translocon, which inhibits the forward movement of VemP and stabilizes its elongation-arrested state by antagonizing the translocation force that otherwise (when Arg85 is mutated) could lead to a rapid arrest cancelation. Thus, a force strong enough to overcome the arrest must be applied in the case of wild-type VemP to make it competent for regulation.
Our experiments demonstrate that the presence of Arg-85 acts as an obstacle for translocation. However, the trans-side motor SecD/F with the aide from PpiD would overcome the obstacle and manage to allow translocation and arrest-cancelation to take place with a physiological efficiency. When Arg-85 is mutated to other amino acid residues, translocation does not meet any obstacle and proceed very rapidly such that we do not see any significant arrest in the Sec-proficient cells. When the signal sequence of VemP is non-functional or the Sec system is inactivated, the elongation arrest occurs normally and continues stably whether or not Arg85 is mutated.
In any case, the VemP arrest cancelation may require a pulling force by the PpiD-SecD/F system in addition to the force generated by SecA, which alone is insufficient. From this line of considerations, we propose that translation and translocation of VemP are tuned to monitor the periplasmic motor activity of the bacterial Sec system. Remarkably, monitoring substrates employ different force-generation mechanisms to enable real-time monitoring of local events of polypeptide translocation, which is superimposed with temporal elements of translation. The notion that the conserved Arg-85 residue confers the PpiD-SecD/F dependency of the arrest-release of VemP requires further experimental verification, including in vitro recapitulation of arrest cancelation by SecA plus ATP vs PpiD-SecD/F plus proton/sodium-motive forces. A single-molecule analysis to measure the pulling force required for the arrest-release of VemP will also be informative.
Interestingly, SecM also possesses a cis-element that is located outside the ribosome in the arrested translation complex and required for the efficient arrest cancelation (Ito et al., 2018; Nakamori et al., 2014). The regulatory target of SecM is SecA (Nakatogawa and Ito, 2001), and its arrest is canceled at an early stage of translocation, before the cleavage of the signal sequence (Mori et al., 2018; Nakatogawa and Ito, 2001). SecM may monitor the SecA-stimulated early translocation event via its cis-element. Thus, a role of the cis-element in SecM should be different with that of Arg-85 in VemP. Our current results, taken together, reveal that different monitoring substrates monitor different sub-steps of translocation, and a cis-element aids the monitoring function by different mechanisms. Our results suggest that pulling forces applied to the ribosome-nascent-chain complexes can be diverse and differentiated to be sensed and processed precisely by regulatory nascent polypeptides, opening up a new dimension of the force-sensing translation arrest.
Materials and methods
Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
---|---|---|---|---|
Strain (E. coli) | MC4100 | This paper | Supplementary file 1 | |
Strain (V. alginolyticus) | 138–2 | This paper | Supplementary file 1 | |
Strain (P1 bacteriophage) | Laboratory stock | CGSC12133 | ||
Recombinant DNA reagent | Plasmids | This paper | Supplementary file 2 | |
Sequence-based reagent | This paper | PCR primers | Supplementary file 3 | |
Antibodies | 1st antibodies | This paper | listed in the below | |
Antibody | Goat Anti-Rabbit IgG (H + L)-HRP Conjugate | Bio-Rad Laboratories | 1706515 | |
Chemical compound | H-p-Bz-Phe-OH | Bachem | F2800 | |
Chemical compound | Methionine, L-[35S] Translation Grade | American Radiolabeled Chemicals | ARS 01014 | |
Chemical compound | ANTI-FLAG M2 Affinity Gel | Sigma-Aldrich | A2220 | |
Chemical compound | nProtein A Sepharose4 Fast Flow | GE Healthcare | 17528004 | |
Chemical compound | Ni-NTA Agarose | QIAGEN | 30250 | |
Commercial kit | ECL Western Blotting Detection Reagents | GE Healthcare | RPN2106 | |
Commercial kit | ECL Prime Western Blotting Detection Reagents | GE Healthcare | RPN2232 | |
Software, Algorithm | Microsoft Excel | Microsoft | ||
Software, Algorithm | Bio-imaging Analyzer BAS-1800, BAS-5000 | Fujifilm/GE Healthcare | ||
Software, Algorithm | Image Qaunt LAS 4000 mini | Fujifilm/GE Healthcare | ||
Software, Algorithm | Multi Gauge | Fujifilm/GE Healthcare |
Bacterial strains, plasmids, and primers
Request a detailed protocolEscherichia coli K12 strains and Vibrio alginolyticus VIO5 strains, plasmids, and primers used in this study are listed in Supplementary files 1, 2, and 3, respectively. Details of the strain and plasmid construction are described in Construction of Mutant Strains and Plasmid Construction, respectively.
Media and bacterial cultures
Request a detailed protocolE. coli cells were grown in L rich medium (10 g/L bacto-tryptone, 5 g/L bacto-yeast extract, 5 g/L NaCl; pH adjusted to 7.2 with NaOH) or M9 synthetic medium (without CaCl2; Miller, 1972) supplemented with maltose (final 0.2%), glycerol (final 0.4%), all amino acids (except Met and Cys; final concentration of 20 μg/mL each). 50 µg/mL ampicillin, 20 µg/mL chloramphenicol, 25 µg/mL kanamycin, 25 µg/mL tetracycline, and 50 µg/mL spectinomycin were added as appropriate for growing plasmid-bearing cells and selection of transformants and transductants. V. alginolyticus cells were grown in VC-rich medium (5 g/L bacto-tryptone, 5 g/L bacto-yeast extract, 4 g/L K2HPO4, 30 g/L NaCl, 2 g/L glucose; Terashima et al., 2010). For induction with arabinose, we used modified VC medium containing 0.2% arabinose instead of 0.2% glucose. 2.5 µg/mL chloramphenicol was added as appropriate for growing plasmid-bearing cells. Bacterial growth was monitored with Mini photo 518R (660 nm; TAITEC Co., Saitama, Japan).
Antibodies
ANTI-FLAG M2 Affinity Gel (anti-FLAG antibody for immunoprecipitation) was purchased from Sigma-Aldrich, Co. LLC (St. Louis, MO). For preparation of an antibody against SecD, two oligopeptides (CYKDSGKKDANG and CYGGKRVLLLSI) were synthesized. They were mixed, conjugated with a carrier protein, keyhole limpet hemocyanin, via the Cys residue attached at their N-terminus and used to raise antibodies in rabbits. Anti-SecD IgGs were affinity-purified and used in the experiments. Anti-uL22, anti-Ffh, and anti-PpiD antibodies were gifts from S. Chiba (Kyoto Sangyo University, Kyoto, Japan), C. A. Gross (University of California at San Francisco, San Francisco, CA) and M. Müller (University of Freiburg, Freiburg, Germany), respectively. Anti-VemP, anti-V.SecD1, and anti-V.SecD2 (Ishii et al., 2015), antibodies as well as anti-SecG (Nishiyama et al., 1993) and anti-MBP (Baba et al., 1990) antibodies were described previously.
Construction of mutant strains
Request a detailed protocolRM3122 (HM1742, ΔsecG::kan), RM3124 (HM1742, ΔppiD::kan), and HM4790 (HM1742, ΔsecB::kan) were constructed by transducing ΔsecG::kan from JW3142 (Baba et al., 2006), ΔppiD::kan from JW0431 (Baba et al., 2006) and ΔsecB::kan from JW3584 (Baba et al., 2006) to HM1742 (Mori and Ito, 2006b), respectively. HM4798 (HM1742, ΔsecB::FRT) was constructed from HM4790 by removing the kan gene using pCP20 (Cherepanov and Wackernagel, 1995). RM2831 (HM1742, ffh-his10) were constructed by essentially the same procedure as the construction of SPA-tag collection strains (Butland et al., 2005). First, a his10-tag::kan fragment having sequences identical to the upstream and downstream regions of the ffh termination codon at its 5’ and 3’ ends, respectively, was PCR-amplified from pRM573 (See the last part of this session) using ffh-his10-f and ffh-his10-r primers. Then, this fragment was integrated into the E. coli DY330 chromosome using the λ-Red recombination system (Yu et al., 2000). After transferring an ffh-his10-tag::kan to HM1742 by P1 transduction, the kan cassette was removed using pCP20 to yield RM2831. RM2834 (HM1742, secY-his10) was constructed in a similar way, except that a different pair of the primers, secY-his10-f and secY-his10-r were used. RM2935 (HM1742, yidC-his10 kan) and RM3032 (HM1742, ppiD-his10 kan) were also constructed similarly using the primer pairs, yidC-his10-f/yidC-his10-r and ppiD-his10-f/ppiD-his10-r, respectively, whereas the kan cassettes of these strains were not removed. AD96 was constructed by transducing secA51(Ts) from MM52 (Oliver and Beckwith, 1981) to KI269 (Akiyama and Ito, 1985).
Vibrio mutant strains RMV2 and RMV7 were constructed using a ‘suicide vector’, pSW7848, carrying the toxin-encoding ccdB gene under the arabinose promoter control (Ishii et al., 2015). A total of 150 μL of an overnight culture of E. coli β3914 cells harboring pRM691 or pRM744 was mixed well with 50 μL of an overnight culture of V. alginolyticus VIO5 strain. Cells were harvested and resuspended in 100 μL of the VC medium and 2.5 μL of the suspensions was spotted on the VC agar medium containing 300 μM 2,6-diaminopimelic acid (DAP) and incubated at 30°C for 6 hr. Then, the cells were streaked on a VC plate containing 2.5 μg/mL chloramphenicol but without DAP to select Vibrio cells in which a plasmid had been integrated on the chromosome. Subsequently, the chloramphenicol-resistant bacteria were grown on VC-0.2% arabinose agar plates to counter-select the plasmid-integrated Vibrio cells. After confirmation of chloramphenicol-sensitivity and arabinose resistance of obtained cells, presence of the introduced mutations was confirmed by colony PCR.
Construction of plasmids
Request a detailed protocolpTS48 was constructed in the same way as the construction of pTS47 (pHM1021-vemP-3xflag-myc; Mori et al., 2018). pRM374 (pTV118N-vemP-3xflag-myc) was constructed by subcloning a NcoI-HindIII fragment carrying the vemP-3xflag-myc prepared from pTS48 into the same sites of pTV118N. pHM1021-vemP(amb)−3xflag-myc plasmids and pTV118N-vemP(amb)−3xflag-myc plasmids shown in Supplementary file 2 were constructed as follows. An amber mutation at the codons corresponding to the amino acid residues, F11, M16, A21, F24, K31, Y36, Q41, S46, N51, F56, E61, S66, S71, D76, F81, W86, R91, D96, V101, N106, V111, D121, Q126, F131, or S136 was introduced into pTS48 by site-directed mutagenesis using a pair of appropriate primers. Then, pTV118N-vemP-3xflag-myc plasmids containing the same amber mutation was constructed by cloning the NcoI-HindIII fragments that had been prepared from the resultant pHM1021-based plasmids into the same sites of pTV118N. For construction of plasmids carrying an amber codon at positions of the other amino acid residues, an amber mutation was first introduced into pRM374 by site-directed mutagenesis. For construction of pHM1021-vemP-3xflag-myc plasmids containing the same amber mutation, the NcoI-HindIII fragments were prepared from the pRM374-based plasmids and sub-cloned into the same sites of pHM1021. Derivatives of pTS48 encoding a VemP-F3M mutant with an amino acid alteration were constructed by site-directed mutagenesis. pRM848 (pHM1021-vemP(F.S., R85W)−3xflag-myc) was constructed from pHM1202 (pHM1021-vemP(F.S.)−3xflag-myc) by site-directed mutagenesis. pRM662 (pBAD24-vemP(R85W)-V.secD2/F2) was constructed from pHM810 (pBAD24-vemP-V.secD2/F2; Ishii et al., 2015) by site-directed mutagenesis. The pHM1021-vemP-secDF2VA (pRM663), pHM1021-vemP(W143A)-V.secD2/F2 (pRM666), and pHM1021-vemP(R85W)-V.secD2/F2 (pRM667) plasmids were constructed by subcloning the NcoI-SphI fragment carrying the V.vemP-secD2/F2 genes with or without the respective mutations that had been prepared from pBAD24-V.vemP-secD2/F2 plasmids (pHM810, pHM846 and pRM662, respectively). pRM520 (pTV118N-his10-vemP-3xflag-myc) was constructed as follows. A his10-vemP-3xflag-myc fragment was PCR-amplified from pTS48 using his10-vemP-f and M4C primers, digested with NcoI and HindIII, and cloned into the same sites of pTV118N. pRM557 (pTV118N-his10-vemP(ΔSS)−3xflag-myc) was constructed by site-directed mutagenesis of pRM520. Derivatives of pRM557 (pRM562 and pRM563) containing a mutation in the vemP gene were also constructed by site-directed mutagenesis.
pRM83c was a constitutive expression vector, in which the operator region lacO1 on the lac promoter of pRM83 (Miyazaki et al., 2016) had been converted from AATTGTGAGCGGATAACAATT to AATTATTGTTAGACAATAATT (the mutated residues are underlined) by successive site-directed mutagenesis as follows. First, the operator region lacO1 of pRM83 was changed from AATTGTGAGCGGATAACAATT to AATTATTGTCGGATAACAATT using lacO1-c-f and lacO1-c-r primers (the mutations introduced were shown in bold). The second mutagenesis was done with the resultant plasmid as a template using lacO1-c2-f and lacO1-c2-r primers to introduce two additional mutations (AATTATTGTCGGACAATAATT). Finally, further site-directed mutagenesis (AATTATTGTTAGACAATAATT) was conducted using lacO1-c3-f and lacO1-c3-r primers to obtain pRM83c. pRM656 (pRM83c-his10-secD/secF) was constructed as follows. A his10-secD/secF fragment was PCR-amplified from pHM735 (Tsukazaki et al., 2011) using his10-secD-f and secF-r primers, digested with HindIII and SalI, and cloned into the same sites of pRM83c. To reduce the expression level of SecD/SecF, the start codon (ATG) for secD on the above plasmid was mutated to TTG by site-directed mutagenesis. pRM661 (pRM83c-ppiD) was constructed as follows. A ppiD fragment was PCR-amplified from a ppiD-his10 plasmid (laboratory stock) using ppiD-f and ppiD-r primers, digested with HindIII and SalI, and cloned into the same site of pRM83c.
The plasmid used for construction of RMV2 (VIO5, ΔppiD) was constructed as follow. First, a DNA fragment containing a V.ppiD gene with an (1 kb) upstream and downstream sequences was amplified from the genome of VIO5 using Va-ppiD-f and Va-ppiD-r primers, and ligated with the BamHI- and SalI-digested pUC118 fragment using In-Fusion HD cloning Kit to generate pRM670. Next, a DNA fragment for the V.ppiD-upstream and downstream region with the entire vector sequence was amplified from pRM670 by PCR using del-Va-ppiD-f and del-Va-ppiD-r primers, and self-ligated using In-Fusion HD cloning Kit to produce pRM674. Finally, ∼2 kbp DNA fragment containing V.ppiD-upstream and -downstream regions was amplified from a pRM674 using pSW-ppiD-f and pSW-ppiD-r primers, and ligated with the NaeI-digested pSW7848 using In-Fusion HD cloning Kit to construct pRM691. The plasmid used for construction of RMV4 (VIO5, Para-V.ffh) was constructed as follow. First, a DNA fragment containing an V.ffh gene was amplified from the genome of VIO5 using Va-ffh-f and Va-ffh-r primers, and ligated with the NcoI- and SphI-digested pBAD24 fragment using In-Fusion HD cloning Kit to generate pRM737. Next, an V.ffh-upstream region that had been amplified from the VIO5 genome using u-ffh-f and u-ffh-r primers and a DNA fragment that had been amplified from the pRM737 using pRM737-f and pRM737-r were ligated using In-Fusion HD cloning Kit to generate pRM740. Finally, ∼3.8 kbp DNA fragment was amplified from the pRM740 plasmid using pSW-ffh-f and pSW-ffh-r primers, and ligated with the NaeI-digested pSW7848 using In-Fusion HD cloning Kit to construct pRM744.
pRM570 (a plasmid carrying the spa-tag and a kan cassette sequences (spa-tag::kan)) was constructed as follows. A spa-tag::kan fragment was amplified from the genome of an ffh-spa-tag strain (Butland et al., 2005) using spa-kan-f and spa-kan-r primers, digested with EcoRI and SalI, and cloned into the same sites of pUC118. The stop codon of spa-tag was changed from TAG to TAA by site-directed mutagenesis to generate pRM570. To construct pRM573 (pUC118-his10-tag::kan), a his10-tag::kan fragment was amplified from pRM570 using his10-kan-f and M4C primers, digested with EcoRI and SalI, and cloned into the same sites of pUC118.
Immunoblotting analysis
Request a detailed protocolThis method was used in Figures 3A–C and 4C–E and Figure 5—figure supplement 1D. Solubilized total proteins were separated by SDS-PAGE and electro-blotted onto a PVDF membrane (Merck Millipore; Billerica, MA). The membrane was first blocked with 5% skim milk in PBST (Phosphate Buffered Saline with Tween 20), and then incubated with anti-SecD (1/2,000 dilution), anti-V.SecD1 (1/2,000), anti-V.SecD2 (1/2,000), anti-PpiD (1/20,000 or 1/50,000), anti-Ffh (1/10,000) or anti-VemP (1/2,000) antibodies After washing with PBST, the membrane was incubated with a horseradish peroxidase (HRP)-conjugated secondary antibody (1/5,000) (Goat Anti-Rabbit IgG (H + L)-HRP Conjugate; Bio-Rad Laboratories, Inc, Hercules, CA) in PBST. Proteins were visualized with ECL Western Blotting Detection Reagents (GE Healthcare UK Ltd, Amersham Place Little Chalfont, England) or ECL Prime Western Blotting Detection Reagents (GE Healthcare) and LAS4000 mini lumino-image analyzer (GE Healthcare).
PiXie analysis
Request a detailed protocolThis analysis was used in Figures 1B–F and 2A, Figure 1—figure supplements 1A and 2–5 and Figure 2—figure supplement 1. Cells were first grown at 30°C in M9-medium supplemented with 2 µg/mL thiamine, 0.4% glycerol, 0.2% maltose, all amino acids (except Met and Cys; final concentration of 20 μg/mL each), 0.5 mM pBPA (H-p-Bz-Phe-OH F-2800; Bachem AG, Bubendorf, Switzerland), and 0.02% arabinose until early log phase. After IPTG induction for 15 min, cells were pulse-labeled with 370 kBq/mL [35S]Met (American Radiolabeled Chemicals, Inc, St. Louis, MO) for 30 s. In the case of the experiments in Figure 2—figure supplement 4, 0.02% NaN3 and [35S]Met were added simultaneously. After addition of excess non-radioactive Met (final conc. 250 µg/mL), a 350 µl portion of the cell cultures was quickly removed and put into wells of a 24-well microtiter plate (AGC Tehcno Glass Co. Ltd, Shizuoka, Japan) on a temperature-controllable and movable stage (MS Tech Co. Ltd., Kyoto, Japan). Cells were kept at 30°C and UV-irradiated for 1 s at appropriate time points during chase using SP-9 equipped with an SFH lens (USHIO Inc, Tokyo, Japan) at a distance of 5 cm. Control samples without UV-irradiation in Figure 2A and Figure 2—figure supplement 1 were also put to the microtiter plate on the stage and treated in the same way except that they were not UV-irradiated. After UV irradiation, total cellular proteins were immediately precipitated with 5% trichloroacetic acid (TCA), washed with acetone, and solubilized in SDS-buffer (50 mM Tris-HCl (pH 8.1), 1% SDS, 1 mM EDTA). The samples were then diluted 33-fold with Triton-buffer (50 mM Tris-HCl (pH 8.1), 150 mM NaCl, 2% Triton X-100, 0.1 mM EDTA). After clarification, samples were incubated with appropriate antibodies and nProtein A Sepharose 4 Fast Flow (GE healthcare) or Ni-NTA Agarose (QIAGEN) at 4°C over-night with slow rotation. Proteins bound to the antibody/ProteinA-Sepharose or Ni-NTA Agarose were recovered by centrifugation, washed with Triton buffer and then with 10 mM Tris-HCl (pH 8.1) and eluted by incubation at 37°C for more than 5 min in SDS-sample buffer (62.5 mM Tris-HCl (pH 6.8), 2% SDS, 10% glycerol, 5 mg/mL bromophenol blue). The isolated proteins were separated by SDS-PAGE, and visualized with BAS1800 or BAS5000 phosphoimager (Fujifilm Co., Tokyo, Japan). Band intensities were quantified using MultiGauge software (Fujifilm). To obtain the graphs in Figure 2B, the band intensity of VemP-FL (open diamonds), VemP-APs (AP-un + AP-pro; the signal intensity of the AP-pro is normalized by the Met content) (closed diamonds) and XLs (colored symbols) in Figure 2A was quantitated.
In vivo stability of the arrest-form of VemP
Request a detailed protocolThe procedure was used in Figures 3A, 4A, D and 5, Figure 2—figure supplement 3, Figure 3—figure supplement 1 and Figure 5—figure supplements 1B and 2. Cells were first grown at 30°C in M9-medium supplemented with 2 µg/mL thiamine, 0.4% glycerol, 0.2% maltose, all amino acids (except Met and Cys) with or without 0.05% arabinose until early log phase. After induction with for 15 min, cells were pulse-labeled with 370 kBq/mL [35S]Met for 30 s. In the case of Figure 2—figure supplement 3 (for analysis of secA51(Ts)), the induction of VemP-F3M was done, at 2 hr after the temperature shift to 42°C. At appropriate time points after addition of excess nonradioactive Met (final conc. 250 µg/mL), total cellular proteins were precipitated with 5% TCA, washed with acetone, and solubilized in SDS-buffer. The samples were subjected to the IP as described above. Isolated proteins were separated by SDS-PAGE, and visualized with BAS1800 phosphoimager. Percentages of the arrested VemP were calculated by the following equation: arrested VemP (%)=100 × [VemP-APs]/[(VemP-FL) + (VemP-APs)], where VemP-APs (in Figure 2B) and VemP-FL are the intensities of the respective bands.
In vivo photo-crosslinking analysis
Request a detailed protocolIn the Figure 4E, Cells were grown at 37°C in L medium containing 0.5 mM pBPA until early log phase and induced with 0.02% arabinose for 1 hr. The half volume of the cell cultures was put on a petri dish at 4°C and UV-irradiated for 10 min using B-100AP UV lamp (365 nm; UVP, LLC., Upland, CA), at a distance of 4 cm. The other half was kept on ice as non-UV-irradiated samples. Total cellular proteins were precipitated with 5% TCAs, washed with acetone, and suspended in SDS-sample buffer. The samples were subjected to SDS-PAGE and immunoblotting analysis.
Appendix 1
Interactions of a VemP nascent chain with Sec translocon and the related components
As described in the main text, the interaction of the signal sequence of VemP with SRP occurs during the targeting of VemP to the translocon. According to the widely accepted model for co-translational translocation, the signal sequence of VemP should interact with the lateral gate of SecY channel and be intercalated into the gate to move towards a lipid phase, at the initial stage of the translocation, following the targeting process (Van den Berg et al., 2004). It is expected that during the above ‘partition’ process, pBPA introduced into the signal sequence might be cross-linked with the lateral gate of SecY. However, we have not detected such SecY-VemP XLs. The signal sequence of VemP is mostly removed at an early stage of translocation, where translation of VemP still remains arrested on the translocon (note that even after pulse-labeling, the arrested VemP molecules are mostly in the processed (AP-pro) form). Thus, even if the pBPA-containing signal sequence of VemP, which had been cleaved off form AP-un, is crosslinked with the SecY, the XLs cannot be isolated by immunoprecipitation using the anti-VemP antibody raised against the epitope in the mature part of VemP (Ishii et al., 2015). Although the XLs might be able to be isolated by using a His-tag attached to SecY, a small size of the signal sequence will cause only a slight retardation in the mobility of the XL bands, making it difficult to distinguish them from a broad SecY band. Also, a low amount of AP-un having pBPA in the signal sequence will hinder detection of its crosslinking with SecY.
We found that the residue 30–60 region and the residue 74–86 region of VemP were corsslinked with PpiD and SecY, respectively (Figure 6B). These results can be nicely explained if we assume that the arrested VemP is inserted into translocon as a hairpin-like structure with its signal sequence partitioned into the lateral gate, as, in this case, the former region will be close to PpiD in the periplasm whereas the latter region will be within or near the translocon channel. If this assumption is correct, the residue 81 and 83 of VemP that were crosslinked with SecG are expected to be located near the cytoplasmic cavity of the SecY channel. The crystal structure of the SecYEG complex determined by Tanaka et al., 2015 reveals that a cytoplasmic loop between the first and the second TM segments of SecG covers the cytoplasmic cavity of the SecY channel at a resting state. It would be thus conceivable that even at the active state, the cytoplasmic loop of SecG exists near the cytoplasmic cavity of SecY. This would provide one explanation for why SecG as well as SecY is cross-linked with a translocating VemP.
Since several studies (Petriman et al., 2018; Sachelaru et al., 2013) reported that the Sec translocon directly interacts with the membrane chaperone, YidC having a large periplasmic domain, one would expect that VemP can be cross-linked with YidC as well. However, we detected no YidC-VemP XL at least in this study. Recent papers suggest that PpiD and YidC associate with Sec translocon to form two distinct subassemblies (Götzke et al., 2014; Jauss et al., 2019). No crosslinking of VemP with YidC can be explained if a nascent VemP polypeptide can specifically recognize and utilize the Sec translocon that forms the complex with PpiD/SecDF to effectively monitor SecD/F function.
Data availability
All data generated and analyzed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 2, 3 and 4, Figure 2-figure supplements 1, 3 and 4 and Figure 5-figure supplements 1 and 2.
References
-
Characterization of cold-sensitive secY mutants of Escherichia coliJournal of Bacteriology 172:7005–7010.https://doi.org/10.1128/JB.172.12.7005-7010.1990
-
Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the keio collectionMolecular Systems Biology 2:2006.0008.https://doi.org/10.1038/msb4100050
-
Cryo-EM structure of the ribosome-SecYE complex in the membrane environmentNature Structural & Molecular Biology 18:614–621.https://doi.org/10.1038/nsmb.2026
-
Involvement of PpiD in Sec-dependent protein translocationBiochimica Et Biophysica Acta (BBA) - Molecular Cell Research 1865:273–280.https://doi.org/10.1016/j.bbamcr.2017.10.012
-
YfgM Is an Ancillary Subunit of the SecYEG Translocon in Escherichia coliJournal of Biological Chemistry 289:19089–19097.https://doi.org/10.1074/jbc.M113.541672
-
Monitoring substrate enables real-time regulation of a protein localization pathwayFEMS Microbiology Letters 365:fny109.https://doi.org/10.1093/femsle/fny109
-
Noncompetitive binding of PpiD and YidC to the SecYEG translocon expands the global view on the SecYEG interactome in Escherichia coliJournal of Biological Chemistry 294:19167–19183.https://doi.org/10.1074/jbc.RA119.010686
-
Mechanisms of cotranslational maturation of newly synthesized proteinsAnnual Review of Biochemistry 88:337–364.https://doi.org/10.1146/annurev-biochem-013118-111717
-
A photo-cross-linking approach to monitor folding and assembly of newly synthesized proteins in a living cellJournal of Biological Chemistry 293:677–686.https://doi.org/10.1074/jbc.M117.817270
-
A photo-cross-linking approach to monitor protein dynamics in living cellsBiochimica Et Biophysica Acta (BBA) - General Subjects 1864:129317.https://doi.org/10.1016/j.bbagen.2019.03.003
-
Identification and characterization of a translation arrest motif in VemP by systematic mutational analysisJournal of Biological Chemistry 293:2915–2926.https://doi.org/10.1074/jbc.M117.816561
-
The sec protein-translocation pathwayTrends in Microbiology 9:494–500.https://doi.org/10.1016/S0966-842X(01)02174-6
-
The long α-Helix of SecA is important for the ATPase coupling of translocationJournal of Biological Chemistry 281:36249–36256.https://doi.org/10.1074/jbc.M606906200
-
Molecular cloning and functional characterization of SecE of a marine bacterium,Vibrio alginolyticusBiochemical and Biophysical Research Communications 251:894–897.https://doi.org/10.1006/bbrc.1998.9573
-
The ribosome as a hub for protein quality controlMolecular Cell 49:411–421.https://doi.org/10.1016/j.molcel.2013.01.020
-
Structural and mechanistic insights into protein translocationAnnual Review of Cell and Developmental Biology 33:369–390.https://doi.org/10.1146/annurev-cellbio-100616-060439
-
YidC occupies the lateral gate of the SecYEG translocon and is sequentially displaced by a nascent membrane proteinJournal of Biological Chemistry 288:16295–16307.https://doi.org/10.1074/jbc.M112.446583
-
Dynamic interaction of the sec translocon with the chaperone PpiDJournal of Biological Chemistry 289:21706–21715.https://doi.org/10.1074/jbc.M114.577916
-
Peculiar properties of DsbA in its export across the Escherichia coli cytoplasmic membraneJournal of Bacteriology 187:3997–4004.https://doi.org/10.1128/JB.187.12.3997-4004.2005
-
Co-translational protein targeting in bacteriaFEMS Microbiology Letters 365:fny095.https://doi.org/10.1093/femsle/fny095
-
Determinants of the quantity of the stable SecY complex in the Escherichia coli cellJournal of Bacteriology 175:7771–7775.https://doi.org/10.1128/JB.175.24.7771-7775.1993
-
Structure-based working model of SecDF, a proton-driven bacterial protein translocation factorFEMS Microbiology Letters 365:fny112.https://doi.org/10.1093/femsle/fny112
Decision letter
-
Suzanne R PfefferSenior and Reviewing Editor; Stanford University School of Medicine, United States
In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.
Acceptance summary:
The study investigates the Vibrio "secretion monitor" VemP, that monirots the secretion capacity of an organism using ribosome stalling. This study has discovered that translation stalling of the secretion monitor VemP in V. alginolyticus is relieved (or cancelled) by the action of PpiD, a periplasmic chaperone that acts with the proteins SecD/F. Failure to relieve the stall allows increased expression of SecD/F to complete this auto-regulatory circuit. The authors further identify a crucial conserved amino acid (R85) in VemP that imposes its dependence on PpiD for translocation.
Decision letter after peer review:
Thank you for submitting your article "Fine interaction profiling of VemP and mechanisms responsible for its translocation-coupled arrest-cancelation" for consideration by eLife. Your article has been reviewed by Suzanne Pfeffer as the Senior Editor, a Reviewing Editor, and three reviewers. The reviewers have opted to remain anonymous.
The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.
As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is "in revision at eLife". Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)
The study investigates the Vibrio "secretion monitor" VemP, a less well understood analog of the better studied SecM of E. coli. Although VemP and SecM are not homologous, they are conceptually similar in serving the function of monitoring the secretion capacity of an organism using ribosome stalling. In the SecM system, a translation stall that occurs early during synthesis is relieved when SecA "pushes" the nascent chain during translocation and thereby applies a stall-cancelling force. When SecA is limiting, the stall persists, which allows SecA to be translated as it is located in the same operon as SecM. The VemP system operates in a roughly analogous way, but exactly how its stall is relieved (i.e., what activity is being monitored by this system) is not as well understood. As VemP is in the SecD/F operon, presumably this is involved, but has not been shown.
To investigate this problem, the authors use a site-specific crosslinking approach that has good time resolution. By systematically placing the photo-crosslinking amino acid along the length of VemP, they nicely map all the physical interactions. Using molecular weight, IPs, and analysis in deletion strains, most (but not all) of the main crosslinking partners are identified. This analysis paints a picture of a series of interactions that involve the ribosome exit tunnel, Ffh (the bacterial SRP homolog), the SecYEG translocon, and the periplasmic protein PpiD. Genetic analysis provides support that Ffh is involved in targeting (an expected result), and that PpiD and SecD/F are involved in cancelling the VemP stall. Crosslinking suggests that PpiD directly interacts with SecD/F, suggesting that they cooperate in stall cancellation. An interesting side observation is that mutation of a conserved arginine in VemP (R85), that seems to be within the SecY channel in the stalled state, causes efficient stall cancellation.
The strengths of the study are the interesting question that is being addressed, the high technical quality of the data, and the very systematic analysis of physical interactions using their time-resolved crosslinking method (termed PiXie). The conclusion that SecD/F and PpiD are involved in cancelling the stall at a late stage of translocation is generally convincing. The study would benefit from some greater specificity controls in a couple of key areas. One item that is poorly examined is the role of R85. Although an extensive analysis of this intriguing finding is beyond the scope of the study, some very straightforward characterisation would substantially add to the study and should be considered.
Essential revisions:
1) The authors need to test the relationship between R85 and the dependence for translocation on PpiD and/or SecDF. The reason this is the most important is because these are the newest and most interesting aspects of the study: R85 is the first example of a residue outside the ribosome tunnel that influences stalling/restarting, and this is the first paper to demonstrate that SecD/F and PpiD are involved in stall cancellation. Whether R85 is important because of this residue imposing PpiD or SecD/F dependence seemed to me essential to address.
The most interesting and satisfying result would be if R85 imposes dependence on SecD/F and PpiD. This would mean that VemP has evolved this otherwise unnecessary residue in order to sense functionality of these factors so it can respond accordingly when they are impaired.
2) Although the authors stated that "the results shown are representatives of three technical replicates" in the legend to Figure 2A, the reviewers ask the authors to show other data using biological replicates to confirm the reproducibility in a supplemental figure. If there is an interactor, the kinetics of which is not reproducible, the reviewers recommend omitting the interactor. Such omission would not change the essential point in this work. Also, overall data interpretation by the authors is not quantitative and thus very difficult to follow. In the revised manuscript, the authors should disclose how they assigned the bands and quantitated the intensities in more detail, not only for Figure 2 but also for other figures, in particular Figure 1.
3) In addition, proof that SecA is involved as their model suggests would complete the story. This should also be a straightforward experiment considering the expertise of the authors.
Reviewer 1:
1) All the VemP-interactors has been identified from the anticipation based on the molecular weights of the crosslinked products. Since the crosslinked products are so many other than those the authors selected, there would be other interactors that might be involved in the arrest/cancelation process. Please discuss.
2) Is the proposed mechanism to pull the VemP nascent chain applicable to that for SecM?
3) The deletion of the ppiD gene causes no detectable defect of outer membrane biogenesis (Justice et al., 2005). Is the contribution of PpiD on the translocation specific to VemP?
4) Some of the labels in Figures (e.g., Figure 1—figure supplement 4, gel for secY-his10 strain) are incorrect.
Reviewer 2:
1) The authors find that Ffh, SecD/F, and PpiD all impact stall cancellation. The specificity of these observations would be greater if the authors could show that a translocon component that is not involved in VemP translocation does not impact the stall or cancellation. For example, does acute depletion of YidC have any effect? This experiment, if feasible, is important to exclude the possibility that any perturbation to protein translocation would impact VemP.
2) The crosslinking result in Figure 4E showing the SecD-PpiD interaction would be more convincing and specific if the BpA were placed in another position in the periplasmic side of SecD/F and shown to NOT crosslink to PpiD. This would help exclude the possibility of promiscuous crosslinking from any periplasmic region of SecD/F due to its general proximity to the periplasmic chaperone PpiD.
3) The authors propose that SecA is involved in translocation based on the effect of N3. However, they do not document an interaction of substrate with SecA or a genetic requirement. A substrate interaction would seem to be a strong prediction of their model. As a number of unidentified high molecular weight crosslinking products are observed in Figure 1—figure supplement 1A, it seems plausible that a direct interaction with SecA is indeed detectable. Have the authors checked this? If so, this would strengthen their study because all physical interactions show in their model would have experimental support (and it would really demonstrate how their PiXiE method can be comprehensive).
4) The discovery of a specific role for R85 is the most intriguing finding in the study, but is hardly explored at all. While many experiments could be proposed that are beyond the scope of this study, the one experiment that I feel is within the scope is to document the (potential) relationship between R85 and translocation-dependence on SecD/F/PpiD. If I have understood the author's model, R85 partially 'clogs' in the SecYEG translocon, which makes translocation dependent on SecD/F/PpiD. It is this dependence on SecD/F/PpiD that makes VemP a monitor of a late step in translocation. It seems important to test whether R85 makes VemP translocation dependent on PpiD, independent of arrest. In this experiment, one could analyse W143A versus W143A/R85A for translocation in WT versus ∆PpiD strains. The aim here is to test whether R85 imposes PpiD-dependence to translocation (by monitoring signal cleavage). If so, this would indicate that VemP has evolved and retained R85 in order to make its translocation and arrest cancellation dependent on PpiD, as speculated by the authors.
5) The colour schemes in Figure 1A and Figure 1—figure supplement 1B are not concordant (for example, uL22 is green in Figure 1A, but in Figure 1—figure supplement 1B green is a 100 kD crosslink; same for other partners). It would be more helpful to a reader if these colours matched up. Perhaps a good solution is to make a hybrid figure that combines all of these observations into one nice panel that is provided in the main figure as a revised Figure 1A. This way, a reader can appreciate an overview of all the crosslinks observed (i.e., Figure 1—figure supplement 1B) together with the subset that were verified by IPs (i.e., Figure 1A). One way to do this is to simply take Figure S1B, and under the respective sized crosslinks, put the corresponding protein and dots where this was verified by IPs (i.e., the information Figure 1A).
6) In the Discussion, the authors claim that their uL22 crosslink is in vivo validation of specific interactions seen by cryo-EM. This conclusion is probably overstated. The photo-cross-linking documents close proximity, but cannot be used to infer specific residue contacts. Perhaps reword this to say that the crosslinking "are consistent with" the previous structure.
Reviewer 3:
1) Most of the experiments were performed by expressing V. alginolyticus VemP in E. coli as heterologous host. I assume that this is necessary because an orthogonal tRNA/tRNA synthetase system for pBpa insertion does not exist for V. alginolyticus. This should be mentioned. It could also help if the authors would briefly summarize what is known about SecYEG, SecA, SRP etc in V. alginolyticus. This could strengthen their arguments that the data they observe in E. coli indeed reflect what likely is happening in the native host.
2) Ffh was found to cross-link to only one position within the signal sequence (A15), which I found surprising (Figure 1E), considering that approx. 15 residues of the signal sequence were tested (Figure 1—figure supplement 1). Residue A15 and H22 also show cross-linking products of 150 kDa and > 150 kDa, what are those? The predicted Ffh cross-link is also very weak and not detected by the VemP antibodies. Only after pull down with Ni-NTA reacting with His-tagged Ffh, the cross-link is visible. The predicted Ffh-VemP cross-link migrates at 55-60 kDa, which does not seem to fit the expected size (50 kDa + 15-17 kDa)? Are the authors really sure that this reflects an SRP cross-link?
3) It would have been expected that the authors also observe XL to SecA, which based on their model should interact with the mature domain of VemP. Has this been tested and have the high MW XL at 150 kDa and > 150 kDa (Figure 1—figure supplement 1) been probed with anti-secA antibodies?
4) Considering their model, it would have been expected that SecY cross-links also to the signal sequence, if this is trapped at the lateral gate during translocation. Trapping of the signal sequence and a hairpin-like insertion of the nascent VemP would explain the cross-links to PpiD at residues 30-60 and cross-links to SecY of down-stream residues. This could suggest that these down-stream residues are inside the SecY channel. Then why do we see SecG? How does this fit to the general geometry of the SecYEG translocon?
5) The sequential interaction profile of VemP is very interesting, although I think one has to be very careful with the interpretation: there is a substantial variation in the amount of AP-un, AP-pro and FL VemP for the different pBpa variants displayed in Figure 2. Therefore, the rather small differences in the decrease of XL products could simply reflect these variations.
Thus, although their interpretation is probably correct and fits to the general concept of co-translational targeting, the quantification shown in Figure 2 likely overestimates the accuracy of the cross-linking method.
6) I understand that the authors found no XL to YidC, although it is in close contact to SecY and has like PpiD a large periplasmic domain. The authors might want to refer to the papers of Götzke et al., (2014) and Jauss et al., (2019), who suggested that PpiD and YidC associate with distinct SecYEG populations. This could explain why PpiD but not YidC is found in their cross-linking approach.
7) The authors should explain why PpiD shows two cross-linking products. Does this reflect XL to AP-un and AP-pro? The same applies to Figure 4E: why does SecD359 shows two PpiD cross-linking products of significant size difference (approx. 25 kDa)?
8) The use of the secY25/pSTV28-syd strain as translocation defective strain is probably not the best choice. Why not using a more defined SecY mutant, like the SecY39 or SecY40 strains that have been characterized in Koreaki Itos lab and other labs. The partial suppression of the secY24 mutant by overexpression of the largely uncharacterized protein Syd introduces an ambiguity that could be easily prevented. Along the same line: if the secY25/pSTV28-syd is indeed translocation deficient, isn't it surprising that full-length VemP and processed VemP/MBP are detectable at all?
9) A general comment regarding the figures and XLs: the color of the arrow heads is difficult to see (with the exception of red) and the color code in the main text and Figure 1—figure supplement 1B does not match.
https://doi.org/10.7554/eLife.62623.sa1Author response
Essential revisions:
1) The authors need to test the relationship between R85 and the dependence for translocation on PpiD and/or SecDF. The reason this is the most important is because these are the newest and most interesting aspects of the study: R85 is the first example of a residue outside the ribosome tunnel that influences stalling/restarting, and this is the first paper to demonstrate that SecD/F and PpiD are involved in stall cancellation. Whether R85 is important because of this residue imposing PpiD or SecD/F dependence seemed to me essential to address.
The most interesting and satisfying result would be if R85 imposes dependence on SecD/F and PpiD. This would mean that VemP has evolved this otherwise unnecessary residue in order to sense functionality of these factors so it can respond accordingly when they are impaired.
We greatly appreciate this highly helpful advice for increasing significance of our finding. According to the suggestion (comment #4) form the reviewer 2, we addressed whether the mutation of the R85 residue cancels the dependency of the VemP translocation on PpiD in the absence of the translation arrest. We first examined effects of the R85W and the W143A mutations, individually or in combination, on the VemP translocation in the wild type and the ΔppiD strains (the data is shown as Figure 5—figure supplement 2). Although the data apparently support that Arg-85 imposes PpiD-dependence in translocation of VemP, it was difficult to obtain a clear conclusion from the data, because the VemP(W143A) underwent reduced, but still significant elongation arrest in the ΔppiD strain. Thus, we next used a VemP(F.S.) mutant, in which the VemP arrest motif sequence had been replaced with an completely different amino acid sequence by a frame shift (F.S.) mutation (Mori et al., (2018)), which allowed us to examine the effect of the R85W mutation on PpiD dependent-VemP translocation under the condition where contribution of the elongation arrest is completely eliminated. The results clearly showed that Arg-85 confers PpiD-dependence to VemP (the experimental data are presented as new Figure 5C). We have described these results and modified the Discussion section accordingly in the revised manuscript. In addition, we have mentioned these results in the Abstract as they should be one of the most important findings obtained in this study, as suggested by the reviewers.
Please note that we have removed the original Figure 5B that represents quantified results of the original Figure 5A, because the data shown in the original Figure 5A was quite clear and the graph in the Figure 5B seemed to be not so informative.
2) Although the authors stated that "the results shown are representatives of three technical replicates" in the legend to Figure 2A, the reviewers ask the authors to show other data using biological replicates to confirm the reproducibility in a supplemental figure. If there is an interactor, the kinetics of which is not reproducible, the reviewers recommend omitting the interactor. Such omission would not change the essential point in this work.
Thank you for the suggestion. We repeated the PiXie experiments for all the VemP(pBPA) derivatives used in the original Figure 2 and Figure 2—figure supplement 1 by using 3 different transformants (biological replicates) to confirm the reproducibility. Although we obtained essentially the same results as the original ones for all the samples examined, the SecY-VemP XLs migrated somewhat broadly on SDS-PAGE and were overlapped with background bands. Unfortunately, in these experiments, the intensities of the background signals substantially were high with unknown reasons. This made exact quantification of the SecY-VemP XLs and their kinetic analysis difficult because they overlap with some of rather strong background signals. Thus, according to the reviewing editor's suggestion, we omitted the kinetic analysis data for the SecY-VemP XLs. Finally, we have removed the original Figure 2 and a part of the original Figure 2—figure supplement 1, and instead included the new Figure 2, in which all the new results of the PiXie experiments obtained with 6 kinds of VemP(pBPA) derivatives are presented.
Also, overall data interpretation by the authors is not quantitative and thus very difficult to follow. In the revised manuscript, the authors should disclose how they assigned the bands and quantitated the intensities in more detail, not only for Figure 2 but also for other figures, in particular Figure 1.
In the experiments shown in the new Figure 1 and the new Figure 1 related supplementary figures, we first assigned bands as the XLs when they were specifically pulled-down by the anti-VemP antibody in the VemP(pBPA)-dependent manner. Regarding the VemP-Ffh XL, we could not detect XLs by using the anti-VemP antibody because a strong background band migrated at the overlapped position with the XL. We thus detected the XL as the one that was specifically pulled-down by Ni-NTA agarose in the VemP(A15pBPA)-dependent manner, when cells expressing the Ffh-His10 was used (Figure 1E, right panel). The assignments were confirmed by one or some of the following experimental results, (i) reactivity of the XLs to the antibody against partner proteins (uL22 (Figure 1B), SecG (Figure 1C), and PpiD (Figure 1—figure supplement 3B)), (ii) disappearance of the XLs in strains lacking the gene for the partner protein (SecG (Figure 1—figure supplement 3A) and PpiD (Figure 1—figure supplement 3B)), and (iii) pull-down of the XLs from cells expressing His10-tagged versions of the partner proteins (SecY(Figure 1D and Figure 1—figure supplement 4A) and PpiD (Figure 1F)). We believe that these results clearly validated our assignment of the XLs.
To show the correctness of the assignment of the XLs in Figure 2, we have added a new Figure as Figure 2—figure supplement 1B, in which the whole gel images of all the pulse-chase experiments shown in the new Figure 2 are presented. The data show that the XLs were generated in a UV-irradiation dependent manner, further confirming that they are pBPA-mediated XLs.
An example (a representative result) of the actual quantification procedure for the immunoprecipitated (IP) bands is shown in the new Figure 2—figure supplement 2 to help understanding by readers. All the raw data used for the quantification are presented in the Source data files. Regarding the Figure 2, all the quantified regions containing IP bands are shown by squares in the representative gel image on the second page of the file. All the quantified and static data of the experimental results have been summarized in the Excel files.
3) In addition, proof that SecA is involved as their model suggests would complete the story. This should also be a straightforward experiment considering the expertise of the authors.
As pointed out by the reviewer 2, we previously showed that the NaN3 (a SecA inhibitor) treatment of cells severely compromised both translocation and arrest-cancelation of VemP (Mori et al., (2018)). Although it strongly suggests involvement of SecA in the translocation of VemP, we understand that we have not demonstrated direct interaction between VemP and SecA, nor provided genetic evidence about involvement of SecA in the VemP translocation. According to the reviewer 2’s comment, we examined export of VemP in a secA51(Ts) mutant cell by pulse-chase experiments. Our results clearly showed that the translocation and arrest cancelation of VemP was severely and specifically retarded at high temperature in the secA51(Ts) mutant cells, but not in its isogenic wild type cells, indicating that SecA is crucial for VemP biogenesis and its arrest cancelation. We have added the new data as Figure 2—figure supplement 3 and inserted description of these results in the Results.
About the VemP-SecA interaction, several unidentified high molecular weight bands that might represent the VemP-SecA XLs have been observed in Figure 1—figure supplement 1. We examined these bands and found that an XL of ~150 kDa, observed with the VemP(L40pBPA) variant, was precipitated with an anti-SecA antibody. However, the PiXie analysis showed that the pulse-labeled SecA-VemP XL remained stable during the chase periods, in sharp contrast to XLs with other proteins shown in the Figure 2. These results suggest that, while the observed SecA-VemP cross-linking could show the ability of SecA to directly recognize VemP, it may not reflect their physiological interaction that occurs during the translocation of VemP. It would be possible that the off-pathway interaction between VemP and SecA can be stable and more easily detected than the physiological one that could occur in a very short time scale. Considering the above points, we did not analyze the XL of ~150 kDa any further. We have added these results as new Figure 1—figure supplement 2 and explained them in the Results in the revised manuscript.
Reviewer 1:
1) All the VemP-interactors has been identified from the anticipation based on the molecular weights of the crosslinked products. Since the crosslinked products are so many other than those the authors selected, there would be other interactors that might be involved in the arrest/cancelation process. Please discuss.
Thank you for the comment. We basically agree with the reviewer's opinion. We understand that a number of extra bands (possible XLs) were detected with many VemP(pBPA) derivatives. It would be possible that some of the uncharacterized bands might represent the XLs with un-identified partner proteins that contribute to the arrest/cancelation process of VemP. We have added description on this point in the Results in the revised manuscript.
2) Is the proposed mechanism to pull the VemP nascent chain applicable to that for SecM?
As described in the manuscript, the arrest cancelation of VemP occurs at a late step in its translocation after the processing of its signal sequence, as a result of co-operative functioning of SecDF and PpiD. On the other hand, the arrest cancelation of SecM seems to occur at an earlier step of translocation, that is, before the processing of the signal sequence. At this step, SecDF and PpiD would not be able to participate in the translocation/arrest-cancelation of SecM. The regulation system for the SecM arrest cancelation would be suitable for directly monitoring function of SecA ATPase whose expression is controlled by SecM. In addition, SecM seems not to possess a residue corresponding to Arg-85 of VemP that plays a crucial role in the cancelation. Therefore, we have stated that the mechanism proposed in this paper would be utilized for the arrest-cancelation of VemP but not for that of SecM. We have briefly discussed the difference between VemP and SecM in theDiscussion in the revised manuscript.
3) The deletion of the ppiD gene causes no detectable defect of outer membrane biogenesis (Justice et al., 2005). Is the contribution of PpiD on the translocation specific to VemP?
Obviously PpiD is not essential for cell viability and biogenesis of major OMPs, as shown by Justice et al. However, their results would not contradict possible contribution of PpiD to transport of some minor secretory proteins. Since PpiD is well-conserved among enterobacteria including E. coli that possess no VemP protein, we think it possible that PpiD plays physiological/regulatory roles in biogenesis of some kinds of secretory proteins even in E. coli, like in the case of VemP. This point has been discussed in the Discussion in the revised manuscript.
4) Some of the labels in Figures (e.g., Figure 1—figure supplement 4, gel for secY-his10 strain) are incorrect.
We apologize for the mistakes. We have corrected the errors.
Reviewer 2:
1) The authors find that Ffh, SecD/F, and PpiD all impact stall cancellation. The specificity of these observations would be greater if the authors could show that a translocon component that is not involved in VemP translocation does not impact the stall or cancellation. For example, does acute depletion of YidC have any effect? This experiment, if feasible, is important to exclude the possibility that any perturbation to protein translocation would impact VemP.
We completely agree with the above comment. It would be important to obtain data showing that a factor not involving in the VemP translocation does not contribute to the arrest cancelation of VemP. Although the reviewer requested us to examine the effect of YidC depletion on the VemP arrest cancelation, we have not performed this experiment as we think that it would be difficult to obtain a clear conclusion by this approach, from the following reasons. (i) A long-term cultivation (about 5-6 hours) will be required for effective depletion of YidC. Because YidC depletion will affect the biogenesis of many membrane proteins including the translocon components, we might observe side effects caused by a reduction of translocon-components after such longer depletion, even if YidC itself is not directly involved in VemP translocation. (ii) On the other hand, even when we observe no effect on the VemP translocation/arrest cancelation upon YidC-depletion, we cannot exclude the possibility that a small amount of YidC is sufficient for the above processes. (iii) indeed, though we have not detected a YidC-VemP XL so far, we cannot exclude the possibility that YidC contributes to VemP translocation.
Instead, we examined the effect of a deletion of the secB gene that encodes a secretion specific chaperone on the VemP arrest cancelation. It is well known that SecB is a member of the Sec translocation pathway and contributes to the post-translational target of substrates to the SecYEG translocon. Our data clearly show that the knock-out of the secB gene severely retards processing of the signal sequence of MBP, a SecB-dependent substrate, but not impact the VemP translocation and its arrest-cancelation. These results not only indicate that perturbation of some aspects of protein translocation does not necessarily affect the VemP translcation/arrest-cancelation, but also reinforce our conclusion that VemP is co-translationally targeted to the translocon via the SRP pathway. We have added these data as the new Figure 3—figure supplement 1 and its description in the Results in the revised manuscript. We thank the reviewer again for the productive suggestion.
2) The crosslinking result in Figure 4E showing the SecD-PpiD interaction would be more convincing and specific if the BpA were placed in another position in the periplasmic side of SecD/F and shown to NOT crosslink to PpiD. This would help exclude the possibility of promiscuous crosslinking from any periplasmic region of SecD/F due to its general proximity to the periplasmic chaperone PpiD.
Thank you for pointing out an important point. We have performed systematic in vivo pBPA cross-linking experiments targeted to many residues locating at the molecular surface of the first periplasmic domain of SecD, and found that only a specific set of the residues (Asp-359 presented in this paper and its neighboring residues) were cross-linked with PpiD, suggesting that a specific region in SecD is involved in its interaction with PpiD.
Since we want to publish the above cross-linking results elsewhere as a part of a separate paper, we would not like to include the results in this manuscript, if possible. However, if you need to see the data in order to review this work, we will be happy to disclose the unpublished data as a confidential information. If so, please let me know.
3) The authors propose that SecA is involved in translocation based on the effect of N3. However, they do not document an interaction of substrate with SecA or a genetic requirement. A substrate interaction would seem to be a strong prediction of their model. As a number of unidentified high molecular weight crosslinking products are observed in Figure 1—figure supplement 1A, it seems plausible that a direct interaction with SecA is indeed detectable. Have the authors checked this? If so, this would strengthen their study because all physical interactions show in their model would have experimental support (and it would really demonstrate how their PiXiE method can be comprehensive).
Thank you for the valuable comments. Please see our response to the reviewing editor’s comment 3.
4) The discovery of a specific role for R85 is the most intriguing finding in the study, but is hardly explored at all. While many experiments could be proposed that are beyond the scope of this study, the one experiment that I feel is within the scope is to document the (potential) relationship between R85 and translocation-dependence on SecD/F/PpiD. If I have understood the author's model, R85 partially 'clogs' in the SecYEG translocon, which makes translocation dependent on SecD/F/PpiD. It is this dependence on SecD/F/PpiD that makes VemP a monitor of a late step in translocation. It seems important to test whether R85 makes VemP translocation dependent on PpiD, independent of arrest. In this experiment, one could analyse W143A versus W143A/R85A for translocation in WT versus ∆PpiD strains. The aim here is to test whether R85 imposes PpiD-dependence to translocation (by monitoring signal cleavage). If so, this would indicate that VemP has evolved and retained R85 in order to make its translocation and arrest cancellation dependent on PpiD, as speculated by the authors.
Thank you for the productive proposal. Please see our response to the reviewing editor’s comment 1.
5) The colour schemes in Figure 1A and Figure 1—figure supplement 1B are not concordant (for example, uL22 is green in Figure 1A, but in Figure 1—figure supplement 1B green is a 100 kD crosslink; same for other partners). It would be more helpful to a reader if these colours matched up. Perhaps a good solution is to make a hybrid figure that combines all of these observations into one nice panel that is provided in the main figure as a revised Figure 1A. This way, a reader can appreciate an overview of all the crosslinks observed (i.e., Figure 1—figure supplement 1B) together with the subset that were verified by IPs (i.e., Figure 1A). One way to do this is to simply take Figure 1—figure supplement 1B, and under the respective sized crosslinks, put the corresponding protein and dots where this was verified by IPs (i.e., the information Figure 1A).
Thank you for your suggestions to improve our presentation. According to the suggestion, the colors of XLs in the Figure 1—figure supplement 1 was coordinated with the corresponding colors used in Figure 1A to increase clarity. In addition, we have modified the Figure 1 by adding a dashed red line that represents positions at which possible cross-linking with PpiD was observed in the Figure 1—figure supplement 1.
Although we deeply appreciate your helpful suggestion, we would like to show the data in the Figure 1A and those in the Figure 1—figure supplement 1B as separate figures, after introduction of several modifications described above. It is because some XLs observed in the Figure 1—figure supplement 1 would represent non-physiological interactions, as we explained above for the SecA-VemP XLs. We think that the separate presentation of the overall crosslinking profile as revealed by anti-VemP IP (Figure 1—figure supplement 1B) and the XLs that would reflect physiological interaction with the conformed partners (Figure 1A) would facilitate correct understanding of the crosslinking data by readers.
6) In the Discussion, the authors claim that their uL22 crosslink is in vivo validation of specific interactions seen by cryo-EM. This conclusion is probably overstated. The photo-cross-linking documents close proximity, but cannot be used to infer specific residue contacts. Perhaps reword this to say that the crosslinking "are consistent with" the previous structure.
Thank you for the suggestion. It is true that the crosslinking does not necessarily indicate the direct physical contact between the crosslinked proteins. We have changed the text in the Discussion in the revised manuscript, as suggested.
Reviewer 3:
1) Most of the experiments were performed by expressing V. alginolyticus VemP in E. coli as heterologous host. I assume that this is necessary because an orthogonal tRNA/tRNA synthetase system for pBpa insertion does not exist for V. alginolyticus. This should be mentioned. It could also help if the authors would briefly summarize what is known about SecYEG, SecA, SRP etc in V. alginolyticus. This could strengthen their arguments that the data they observe in E. coli indeed reflect what likely is happening in the native host.
Thank you for the valuable comments. According to the suggestions, we have made several additions and modifications to the text in the last part of Introduction, which includes explanation of our heterologous experimental system, brief introduction of the Sec system in Vibrio species and a statement about significance of this study even using the heterologous system.
2) Ffh was found to cross-link to only one position within the signal sequence (A15), which I found surprising (Figure 1E), considering that approx. 15 residues of the signal sequence were tested (Figure 1—figure supplement 1). Residue A15 and H22 also show cross-linking products of 150 kDa and > 150 kDa, what are those? The predicted Ffh cross-link is also very weak and not detected by the VemP antibodies. Only after pull down with Ni-NTA reacting with His-tagged Ffh, the cross-link is visible. The predicted Ffh-VemP cross-link migrates at 55-60 kDa, which does not seem to fit the expected size (50 kDa + 15-17 kDa)? Are the authors really sure that this reflects an SRP cross-link?
With respect to the VemP-Ffh crosslinking, we quantitated the signal intensities of the regions corresponding to the migrating position of the VemP(A15pBPA)-Ffh XL for all the lanes in the gel shown in Figure 1—figure supplement 4B and found that several VemP derivatives containing pBPA at the positions 11, 18, 31, 36 and 46 gave slight but significant signals, suggesting that crosslinking with Ffh occurs not only at the A15 position but also at the other positions within or adjacent to the signal sequence. Thus, we suppose that the Ffh can interact with the VemP signal sequence at several positions (although the interaction at the position A15 might play a major role in this interaction).
It is sometimes observed that apparent molecular sizes of XLs estimated from their mobilities on SDS-PAGE don’t well match their sizes calculated as the sum of molecular sizes of the cross-linked proteins. We think that mobilities of XLs on SDS-PAGE depend on not only molecular sizes but also their shapes (ex. a T-like shape or a X-like shape). Probably, the Ffh-VemP XL would exhibit an anomalous mobility due to the above reason. We concluded the XL observed for VemP (A15pBPA) to be the XL with SRP(Ffh), from the following reasons. (i) The XL was reproducibly and specifically pulled down by Ni-NTA agarose, only when we used the cells expressing His-tagged version of Ffh. (ii) The XL was significantly enhanced by compromising the targeting step of VemP using NaN3 treatment of the cells (See Figure 2—figure supplement 4), which is expected to stabilize the VemP-SRP interaction. (iii) The generation of the VemP-SRP XL is consistent with our genetic/biochemical data that SRP contributes to both VemP translocation and its arrest-cancelation.
3) It would have been expected that the authors also observe XL to SecA, which based on their model should interact with the mature domain of VemP. Has this been tested and have the high MW XL at 150 kDa and > 150 kDa (Figure 1—figure supplement 1) been probed with anti-secA antibodies?
Thank you for the comments. The reviewing editor and the reviewer 2 also raised similar questions. Please see our response to the reviewer editor’s comment 3.
4) Considering their model, it would have been expected that SecY cross-links also to the signal sequence, if this is trapped at the lateral gate during translocation. Trapping of the signal sequence and a hairpin-like insertion of the nascent VemP would explain the cross-links to PpiD at residues 30-60 and cross-links to SecY of down-stream residues. This could suggest that these down-stream residues are inside the SecY channel. Then why do we see SecG? How does this fit to the general geometry of the SecYEG translocon?
As discussed above, the signal sequence of VemP should interact with the lateral gate of SecY at an early step of its translocation and could generate a XL, when pBPA is introduced into the VemP signal sequence. However, the signal sequence of VemP is mostly removed at an early time point of translocation, where translation of VemP is still arrested (note that even after pulse-labeling, the arrested VemP molecules are mostly in the processed form). Thus, even if the pBPA-containing signal sequence of VemP, which had been cleaved off form AP-un, is crosslinked with the SecY, the XLs cannot be isolated by immunoprecipitation using the anti-VemP antibody raised against the epitope in the mature part of VemP. Although the XLs might be able to be isolated by using a His-tag attached to SecY, a small size of the signal sequence will cause only a slight retardation in the mobility of the XL bands, making it difficult to distinguish them from a broad SecY band. Also, a low amount of AP-un having pBPA in the signal sequence will hinder detection of its crosslinking with SecY.
Concerning the cross-linking with SecG, the crystal structure of the SecYEG complex determined by Tanaka et al., (2015) reveals that the transmembrane region of SecG is located on the exterior surface of the N-terminal half of the SecY channel, and the cytoplasmic loop between the TMs 1 and 2 of SecG covers the cytoplasmic cavity of the SecY channel at a resting state. It would be thus conceivable that even at the active state, the cytoplasmic loop of SecG exists near the cytoplasmic cavity of SecY. This would provide one explanation for why SecG as well as SecY is cross-linked with a translocating VemP.
Although we appreciate your comments, which should be useful and very interesting to the researchers working in this field of study, we are afraid that inclusion of the discussion on this point in the main text may interrupt the central story of this study and thus hinder its understanding by many of readers of this journal that would be mostly non-specialists. Thus, we would like to include the above discussions as the Appendix 1, if possible.
5) The sequential interaction profile of VemP is very interesting, although I think one has to be very careful with the interpretation: there is a substantial variation in the amount of AP-un, AP-pro and FL VemP for the different pBpa variants displayed in Figure 2. Therefore, the rather small differences in the decrease of XL products could simply reflect these variations.
Thus, although their interpretation is probably correct and fits to the general concept of co-translational targeting, the quantification shown in Figure 2 likely overestimates the accuracy of the cross-linking method.
We appreciate your comments. We agree that we cannot completely exclude the possibility that difference in the rates of disappearance of these XLs is not due to difference in the timing of the interactions, but is due to variations in the amounts of the VemP(pBPA) derivatives. However, the amounts of AP-un, AP-pro and FL VemP are comparable among the VemP(pBPA) derivatives used in the kinetic study. Also, while we analyzed only one XL for each of uL22 and Ffh as we unfortunately detected a clear crosslinking at a single position for these proteins, two different XLs were used for kinetic analysis of each of SecG and PpiD, and they gave consistent results. In addition, as pointed out by the reviewer, our results are nicely fit with the general concept of co-translational targeting. We thus think that our interpretation is well grounded, but modified the relevant text to make it a more careful description. Specifically, we have changed the words “We demonstrated” in the original manuscript to “The kinetic analyses suggest” in the Discussion in the revised manuscript.
6) I understand that the authors found no XL to YidC, although it is in close contact to SecY and has like PpiD a large periplasmic domain. The authors might want to refer to the papers of Götzke et al., (2014) and Jauss et al., (2019), who suggested that PpiD and YidC associate with distinct SecYEG populations. This could explain why PpiD but not YidC is found in their cross-linking approach.
Thank you for the information. It could be a reason why we did not detect a VemP-YidC XL. We have discussed this point in the Appendix 1 described above.
7) The authors should explain why PpiD shows two cross-linking products. Does this reflect XL to AP-un and AP-pro? The same applies to Figure 4E: why does SecD359 shows two PpiD cross-linking products of significant size difference (approx. 25 kDa)?
We think that pBPA introduced at position 359 in SecD can be cross-linked with two different positions in PpiD that could be located distantly in the primary structure. As described above, it is often observed that XLs generated from the same two proteins exhibit different gel mobilities when their crosslinking sites are different. This is briefly explained in the Results.
8) The use of the secY24/pSTV28-syd strain as translocation defective strain is probably not the best choice. Why not using a more defined SecY mutant, like the SecY39 or SecY40 strains that have been characterized in Koreaki Itos lab and other labs. The partial suppression of the secY24 mutant by overexpression of the largely uncharacterized protein Syd introduces an ambiguity that could be easily prevented. Along the same line: if the secY25/pSTV28-syd is indeed translocation deficient, isn't it surprising that full-length VemP and processed VemP/MBP are detectable at all?
Thank you for the critical comments. We have previously demonstrated that the secY24/psyd system used in this study as well as the secY39 mutation severely compromised translocation of VemP and stabilized its arrested form (Mori et al., (2018)). We indeed observed small amount of full-length VemP and processed VemP/MBP in the secY24/psyd system. However, similar results were obtained, even when the secY39 mutation was used (Please compare of Figure 1B, lanes 1 to 3 and 10 to 12 (secY24/psyd) with Figure S2A (secY39) in the above Mori et al., paper), indicating that complete inhibition of protein translocation is quite difficult using these systems (actually the secY24/psyd system appears to exert slightly stronger effects than secY39). As you mentioned, inactivation of the Sec system using the secY24/psyd was not complete, but we think it sufficient to evaluate the effects of the mutations of VemP on its translocation. Indeed, we were able to detect clear difference between the behaviors of VemP(W143A) and VemP(R85W) under the SecY24/Syd-induced translocation-compromised condition. These previous results and observations, we think, justifies the utilization of the secY24/psyd system.
9) A general comment regarding the figures and XLs: the color of the arrow heads is difficult to see (with the exception of red) and the color code in the main text and Figure 1—figure supplement 1B does not match.
We have changed the color of the arrow heads. Details have been described in the response to the reviewer 2’s comment 5. Please see above.
In addition, please note that we have corrected both the average values of the Ara (-) sample (shown as purple squares) and the lengths of the corresponding error bars in the graph of the Figure 3A, because we found mistakes in the quantified data used for preparation of the original Figure 3A. The corrections do not affect the conclusion. We apologize for the careless mistakes.
We have also included the source data for Figure 2, Figure 3 and Figure 4 and Figure 2—figure supplement 1, Figure 2—figure supplement 3 and Figure 2—figure supplement 4 and Figure 5—figure supplement 1 and Figure 5—figure supplement 2.
https://doi.org/10.7554/eLife.62623.sa2Article and author information
Author details
Funding
Japan Society for the Promotion of Science (18H06047)
- Ryoji Miyazaki
Japan Society for the Promotion of Science (19K21179)
- Ryoji Miyazaki
Japan Society for the Promotion of Science (20K15715)
- Ryoji Miyazaki
Japan Society for the Promotion of Science (15H01532)
- Yoshinori Akiyama
Japan Society for the Promotion of Science (18H02404)
- Yoshinori Akiyama
Japan Society for the Promotion of Science (17H05666)
- Hiroyuki Mori
Japan Society for the Promotion of Science (17H05879)
- Hiroyuki Mori
Japan Society for the Promotion of Science (17K07334)
- Hiroyuki Mori
Japan Society for the Promotion of Science (20K06556)
- Hiroyuki Mori
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Acknowledgements
We thank Shinobu Chiba, Carol A Gross and Matthias Müller for providing antibodies, NBRP (NIG, Japan): E. coli for bacterial strains, Koreaki Ito for critical reading and editing of the manuscript, and our laboratory members for discussion.
Senior and Reviewing Editor
- Suzanne R Pfeffer, Stanford University School of Medicine, United States
Version history
- Received: August 31, 2020
- Accepted: December 11, 2020
- Accepted Manuscript published: December 15, 2020 (version 1)
- Version of Record published: January 8, 2021 (version 2)
- Version of Record updated: January 13, 2021 (version 3)
Copyright
© 2020, Miyazaki et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 672
- Page views
-
- 112
- Downloads
-
- 7
- Citations
Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Biochemistry and Chemical Biology
- Cell Biology
The ATPase p97 (also known as VCP, Cdc48) has crucial functions in a variety of important cellular processes such as protein quality control, organellar homeostasis, and DNA damage repair, and its de-regulation is linked to neuromuscular diseases and cancer. p97 is tightly controlled by numerous regulatory cofactors, but the full range and function of the p97–cofactor network is unknown. Here, we identify the hitherto uncharacterized FAM104 proteins as a conserved family of p97 interactors. The two human family members VCP nuclear cofactor family member 1 and 2 (VCF1/2) bind p97 directly via a novel, alpha-helical motif and associate with p97-UFD1-NPL4 and p97-UBXN2B complexes in cells. VCF1/2 localize to the nucleus and promote the nuclear import of p97. Loss of VCF1/2 results in reduced nuclear p97 levels, slow growth, and hypersensitivity to chemical inhibition of p97 in the absence and presence of DNA damage, suggesting that FAM104 proteins are critical regulators of nuclear p97 functions.
-
- Biochemistry and Chemical Biology
- Epidemiology and Global Health
Background: High levels of circulating adiponectin are associated with increased insulin sensitivity, low prevalence of diabetes, and low body mass index (BMI); however, high levels of circulating adiponectin are also associated with increased mortality in the 60-70 age group. In this study, we aimed to clarify factors associated with circulating high-molecular-weight (cHMW) adiponectin levels and their association with mortality in the very old (85-89 years old) and centenarians.
Methods: The study included 812 (women: 84.4%) for centenarians and 1,498 (women: 51.7%) for the very old. The genomic DNA sequence data were obtained by whole genome sequencing or DNA microarray-imputation methods. LASSO and multivariate regression analyses were used to evaluate cHMW adiponectin characteristics and associated factors. All-cause mortality was analyzed in three quantile groups of cHMW adiponectin levels using Cox regression.
Results: The cHMW adiponectin levels were increased significantly beyond 100 years of age, were negatively associated with diabetes prevalence, and were associated with SNVs in CDH13 (p = 2.21 × 10-22) and ADIPOQ (p = 5.72 × 10-7). Multivariate regression analysis revealed that genetic variants, BMI, and high-density lipoprotein cholesterol (HDLC) were the main factors associated with cHMW adiponectin levels in the very old, whereas the BMI showed no association in centenarians. The hazard ratios for all-cause mortality in the intermediate and high cHMW adiponectin groups in very old men were significantly higher rather than those for all-cause mortality in the low level cHMW adiponectin group, even after adjustment with BMI. In contrast, the hazard ratios for all-cause mortality were significantly higher for high cHMW adiponectin groups in very old women, but were not significant after adjustment with BMI.
Conclusions: cHMW adiponectin levels increased with age until centenarians, and the contribution of known major factors associated with cHMW adiponectin levels, including BMI and HDLC, varies with age, suggesting that its physiological significance also varies with age in the oldest old.
Funding: This study was supported by grants from the Ministry of Health, Welfare, and Labour for the Scientific Research Projects for Longevity; a Grant-in-Aid for Scientific Research (No 21590775, 24590898, 15KT0009, 18H03055, 20K20409, 20K07792, 23H03337) from the Japan Society for the Promotion of Science; Keio University Global Research Institute (KGRI), Kanagawa Institute of Industrial Science and Technology (KISTEC), Japan Science and Technology Agency (JST) Research Complex Program 'Tonomachi Research Complex' Wellbeing Research Campus: Creating new values through technological and social innovation (JP15667051), the Program for an Integrated Database of Clinical and Genomic Information from the Japan Agency for Medical Research and Development (No. 16kk0205009h001, 17jm0210051h0001, 19dk0207045h0001); the medical-welfare-food-agriculture collaborative consortium project from the Japan Ministry of Agriculture, Forestry, and Fisheries; and the Biobank Japan Program from the Ministry of Education, Culture, Sports, and Technology.